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^Abstract 
Nicotine is the most addictive and pharmacologically active component of 
tobacco products. For many centuries it has been consumed by humans for pleasure in 
different forms of tobacco. More recently it has been available as a pharmaceutical agent 
in the form of nicotine containing gum, patches, or other products, as an aid to smoking 
cessation. It has also been used to supplement therapy for illness including Alzheimer's 
disease, ulcerative colitis, Parkinson's disease, and Tourette's syndrome. However, 
because of nicotine's addictive property and its effects on various body systems including 
cardiovascular, pulmonary, gastrointestinal, urogenital, pancreatic, nervous and immune 
systems there are apprehensions about its use as a therapeutic agent. Even the non-
smokers are exposed to nicotine due to the ubiquitous presence of tobacco smoke in the 
environment, and also from ingestion of certain foods and beverages. The toxic effect of 
nicotine is being exploited for its use as an insecticide in agriculture and horticulture. 
Thus, man is all the time exposed to nicotine in one form or the other. The importance of 
nicotine in humans is thus, related to its pleasurable effects as well as its possible role in 
tobacco related disorders. 
Nicotine is an agonist at nicotinic acetylcholine receptors (nAChRs), which are 
found on various cells throughout the body. It is a toxic component of cigarettes and 
smokeless tobacco. It is not only toxic by itself but also enhances toxicity of many other 
compounds. Many reports are available explaining the adverse effects of nicotine on 
various body systems. Nicotine has also been reported to inhibit apoptosis in different 
cell lines, which is an important factor in the development of various pathological 
conditions. It is also well established that nicotine is the major immunotoxic component 
of tobacco smoke. But, practically little information is available on its effect on DNA. 
Although, a bulk of literature is available demonstrating cigarette smoke to be an 
established carcinogen and it is also known that some carcinogens are formed during the 
curing process of tobacco by nitrosation of nicotine and related alkyloids, the 
carcinogenicity of nicotine itself is still questionable. In view of this, efforts were made in 
the present study to analyze the direct damage of nicotine to DNA, if any, and to use the 
nicotine modified DNA as a probe to detect the extent of DNA damage in smokers and 
cancer patients. For this purpose, commercially available calf thymus DNA was purified 
and modified by nicotine under UV irradiation. The structural and conformational 
alterations in DNA following modification by nicotine were studied by UV and 
fluorescence spectroscopy, thermal denaturation studies, hydroxyapatite column 
chromatography and nuclease SI sensitivity assay. Physicochemical properties of 
nicotine and unmodified DNA were also studied. The UV spectra of nicotine modified 
DNA, which is abbreviated as Nic*DNA (-Nic), exhibited hypochromicity at Xmax over 
the unmodified DNA, reflecting the modification of bases in the modified DNA. The 
fluorescence spectrum of Nic*DNA (-Nic) showed lower fluorescence intensity than 
native DNA, suggesting the generation of singe strand breaks in the modified DNA. The 
Tm of Nic*DNA (-Nic) was found to be 80°C, whereas, native DNA showed Tm of 
88°C. A net decrease of 8°C in the Tm value of Nic*DNA (-Nic) indicates partial 
destruction of its secondary structure. The decreased affinity of Nic*DNA (-Nic) towards 
hydroxyapatite column also showed presence of single strand breaks in Nic*DNA (-Nic). 
These single stand breaks in Nic*DNA (-Nic) were found to be large enough to act as 
substrates for S1 digestion. 
UV irradiation of nicotine resulted in generation of reactive oxygen species, in 
particular, superoxide anion radical. The generation of the radical was confirmed by 
using superoxide dismutase, a specific quencher of the radical. 
To probe the antigenicity of nicotine and nicotine modified DNA, antibodies were 
raised in rabbits. In order to check the effect of excess of nicotine in DNA samples, two 
variants of nicotine modified DNA were used for immunization: Nic*DNA (-Nic), in 
which excess nicotine was removed once the DNA was modified, and Nic*DNA (+Nic) 
in which excess nicotine was not removed. Unlike native DNA both the variants were 
found to be highly immunogenic, with titre of 1:12800 and >1:125600, respectively. A 
Ill 
higher titre in the latter was due to presence of excess nicotine. Nicotine as well as native 
DNA when immunized separately could render a poor immune response. Thus, it can be 
inferred that DNA is transformed into an immunogenic state following modification by 
nicotine. For the sake of simplicity, further studies were carried out using Nic*DNA (-
Nic) only. Modified DNA or antigen means Nic*DNA (-Nic) throughout the study unless 
mentioned otherwise. Immunoglobulin G was isolated from immune serum obtained 
from the rabbit immunized with Nic*DNA (-Nic). Anti-Nic*DNA (-Nic) antibodies 
showed preferential binding to Nic*DNA (-Nic) when compared to the native DNA as 
depicted by ELISA and gel retardation assay. Preimmune IgG as negative control showed 
negligible binding to Nic*DNA (-Nic). 
Sera of smokers with varying smoking habits were screened for presence of 
circulating antibodies against native DNA and Nic*DNA (-Nic). Out of the 40 sera 
tested, all showed higher recognition of Nic*DNA (-Nic) over native DNA. Moreover a 
direct relationship was observed between the extent of recognition of Nic*DNA (-Nic) 
and smoking status, e.g., the sera showing the highest binding to Nic*DNA (-Nic) were 
from chain smokers and sera showing less recognition of Nic*DNA (-Nic) were from 
occasional smokers. The preference of antibodies in smokers sera to Nic*DNA (-Nic) 
over native DNA was further confirmed by inhibition ELISA. 
Similarly, sera of various cancer patients were tested to detect the presence of 
circulating antibodies against native DNA and Nic*DNA (-Nic). All the sera tested 
showed higher binding to Nic*DNA (-Nic) than native DNA in direct binding ELISA 
studies. The binding specificity of antibodies in selected sera to native DNA and 
Nic*DNA (-Nic) was assessed by competitive binding assay. Two sera of lung cancer 
were tested and both showed higher reactivity with Nic*DNA (-Nic) than native DNA. 
One of them showed an inhibition as high as 76% with Nic*DNA (-Nic). Out of the two 
sera of oral cancer patients tested, both showed higher inhibition with Nic*DNA (-Nic) 
when compared to its unmodified analog. In head and neck cancer category also, two sera 
were tested and both showed remarkably higher inhibition with Nic*DNA (-Nic). One 
IV 
serum each from cancer of bladder, larynx and pharynx was tested and all the three sera 
showed comparatively higher inhibition with Nic*DNA (-Nic) than native DNA. 
From this study, it can be concluded that nicotine causes damage to DNA in in 
vitro systems. This damage is further enhanced if modification of DNA by nicotine is 
carried out in presence of UV irradiation, which is due to generation of oxygen free 
radicals, particularly superoxide anion radical under UV light exposure. Although 
nicotine itself is a poor immunogen, modification of DNA by nicotine renders the DNA 
to be highly immunogenic. The antibodies generated are more specific towards the 
modified DNA than the unmodified DNA. It is postulated that nicotine modified DNA 
may play a role in probing the extent of damage to DNA in smokers. The nicotine 
modified DNA may also play a role in the detection of circulating antibodies in cancer. 
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Introduction 
Watson and Crick (1953) first described the familiar right-handed helical form of 
DNA. In a fully hydrated medium, DNA is found in, what is called the B-form 
(Langridge et al, 1960) and is the most accepted structure of DNA molecule in solution. 
A number of variations in conformation of this basic structure have been described 
(Adams et al, 1981) and are in equilibrium with each other (Rich et al, 1984; 
Pechenaya, 1993). The major physical evidence for the structure of DNA comes from X-
ray diffraction studies of fibers (Langridge et al, 1960). DNA double helix can adopt 
multiple conformations such as A, B and Z, each family having its own intrinsic 
restrictions on chain folding and structure (Watson and Crick, 1953; Amott, 1976; Drew 
and Dickerson, 1981). A-DNA is formed under conditions of low water content and is 
usually not associated with living system (Saenger, 1984; Setlow, 1992). It is 
characterized by more base pairs per turn of the helix and a wider minor groove than B-
DNA. Unlike A and B-forms, Z-DNA has a left-handed helix and phosphate groups in its 
backbone are zigzagged (Rich et al, 1984; Pietrasanta et al, 1994). Triple stranded 
nucleic acids have also been found to exist in DNA (Mirkin et al, 1987; Htun and 
Dalberg, 1989). A typical example is the formation of triple stranded DNA as an 
intermediate in the action of E.coli. recombination enzyme Rec A (Camerini - Otero and 
Hseih, 1993). Other conformations include the cruciform structure, widely found in the 
eukaryotic genome (Wilson and Thomas, 1974; Lu et al, 1992) and quadruple-stranded 
nucleic acids (Rich, 1958). The DNA double helix is both deformed and made 
deformable by its local base sequence, whereas, other regions may be made especially 
susceptible to a change in conformation when the helix interacts with neighbors - a 
protein molecule, drug molecule, or an adjacent DNA helix in crystal lattice. Thus DNA 
has been shown to be a molecule with a high degree of flexibility, whose structure 
depends on interaction with other molecules (Travers, 1989). DNA can undergo all kinds 
of structural and chemical modifications when exposed to internal (spontaneous) or 
external (environmental) damaging factors (Rao, 1993; Wiseman and Halliwell, 1996; 
Henle and Linn, 1997). Various causative agents, that induce damage to DNA in living 
organisms, have been summarized in Table 1. 
Table 1 
Various endogenous and exogenous sources of DNA damage 
Endogenous (spontaneous) sources 
Normal body temperature (37 ° C) 
Normal cellular metabolism * 
Free radicals produced during metabolism 
Errors in DNA replication and repair 
High levels of reducing sugars 
Methylating compounds like S-adenosyl methionine 
Exogenous (environmental) sources 
Dietary mutagenic compounds 
UV and ionizing radiations like X-rays, y-rays 
Free radicals (produced because of a variety of factors including 
ionizing radiations) 
Heavy metals 
Ultrasound 
Adapted from Rao, K.S. (1993) Mol. Neurobiol. 7: 23-48. 
Antigenicity of DNA 
The antigenic property of nucleic acids was recognized much later than those of 
proteins and polysaccharides. Early reports indicated the presence of anti-DNA 
antibodies in patients with systemic lupus erythematosus (SLE) and identified DNA as 
the reactant for these antibodies (Cepellini et al, 1957; Robbins et al., 1957; Seligmann, 
1957). In the early 1960s, methods were developed for the experimental induction of 
antibodies to nucleic acids (Levine et al, 1960; Erlanger and Beiser, 1964; Plescia et al., 
1964; Halloran and Parker, 1966). Exogenous native B-DNA has not been immunogenic 
in experimental animals. Immunization of experimental animals with denatured DNA, 
synthetic polynucleotides, double-stranded RNA, left-handed Z-DNA, chemically 
modified DNA or certain helical synthetic polynucleotides has induced immune 
responses (Braun and Lee, 1988; Garg and Ali, 1998). An important property of the 
resulting antibodies is that they react selectively with the immunogen (Stollar, 1986) 
The DNA molecule has several unique features, which have a direct bearing on its 
immune reactions. First, it appears in nature in different helical forms including both 
right-handed (A- and B-DNA) and left-handed (Z-DNA) helix (Setlow, 1992). The 
second feature of DNA antigen is its multi-determinant nature. DNA is an acidic polymer 
with repeating units both in terms of the nucleotides and the regular turns of the helix. 
The third feature and perhaps, its most intriguing one, is its polyanionic nature. The 
double helical DNA has a hydrophobic core of stacked heterocyclic bases and a soluble 
sugar-phosphate backbone with highly acidic phosphate residues. The phosphate residues 
make DNA a notoriously sticky antigen. The polyanionic nature of the DNA antigen has 
a direct effect on the clinical assay of anti-DNA antibodies. Many serum proteins are 
capable of binding to DNA under physiological conditions (Eilat, 1986) 
While native B-DNA is non-immunogenic, the left-handed Z-DNA is a potent 
immunogen (Lafer et al., 1981; Madaio et al., 1984) inducing antibodies that are 
selective and specific (Zarling et al., 1984). Chemically or physically modified DNA or 
helical structures that differ significantly from B-DNA are much stronger immunologic 
stimuli than native DNA and most of the antibodies induced by modified native DNA do 
not react with the unmodified DNA (Anderson et al, 1988a). Calf thymus DNA modified 
with drugs, hormones, free radicals etc. has been reported to induce antibodies against the 
modified polymer (Alam and AH, 1992; Arif et al, 1994; Moinuddin and Ali, 1994; 
Arjumand et al, 1995; Ara and Ali, 1995). Several polynucleotides, which differ in 
conformation from the B-DNA helical conformation, are much stronger immunogens 
than native B-DNA (Braun and Lee, 1988). Polynucleotides of B-conformation become 
immunogenic after modification with furocoumarins (Arif and Ali, 1996). Studies have 
shown that DNA complexes with a synthetic peptide Fus-I can induce an anti-dsDNA 
response in mice (Desai et al, 1993). Anti-DNA antibodies may also result by 
autoimmunization with chromatin, rather than native DNA (Theofilopoulos, 1995). In 
contrast to mammalian DNA, bacterial DNA can induce a variety of responses in normal 
humans as well as animals. A surprising finding was the recognition of bacterial DNA by 
normal human sera (Karounos et al, 1988). Fredriksen et al (1993) reported the 
recognition of DNA from BK polyoma virus by normal human sera. Studies have also 
demonstrated that complexes of bacterial DNA and MBSA are immunogenic in normal 
mice (Gilkeson et al, 1989) 
It has been reported from our laboratory that immunization of reactive oxygen 
species modified DNA induces antibodies, which exhibit polyspecificity (Ara and Ali, 
1992; 1993; Alam et al, 1993) and recognize B-, A- and allied conformations of DNA 
(Ara and Ali, 1995). Monoclonal antibodies against ROS-DNA have been used as an 
immunochemical probe to detect oxidative DNA lesions in cancer, aging and SLE 
(Ashok et al, 1997). The female sex hormone (estradiol) in conjugation with DNA 
produced non-precipitating antibodies (Moinuddin and Ali, 1994). The photo-crosslink 
between DNA and 8-methoxypsoralen (8-MOP) was observed to be highly immunogenic 
inducing high titer antibodies (Arif and Ali, 1996). 
Nicotine 
Tobacco use and exposure is the single most important source of preventable 
morbidity, disability and premature mortality (Bartal, 2001). At present, tobacco related 
diseases cause over 4.2 million deaths annually (West et al, 2003) and WHO estimates 
that tobacco will become the largest single health problem by 2020 causing an estimated 
8.4 million deaths annually (Vainio et al, 2001). In the United States alone, cigarette 
smoking is related to 431,000 deaths per year. Tobacco contains more than 4,500 
compounds (Sopori, 2002). The tobacco smoke can be divided into a gaseous phase and a 
phase made up of particles. The principal harmful components of the gaseous part are 
carbon monoxide, nitrogen oxide, ammonia and volatile hydrocarbons (Gandini et al, 
1997). The particulate (tar) phase contains at least 3500 compounds and most of the 
carcinogens (Hoffmann and Hecht, 1990). The main component of the particle phase is 
nicotine (Gandini et al, 1997). 
Nicotine is one of the few natural liquid alkaloids, volatile base, colorless, soluble 
in lipid as well as water, and forms hydro-soluble salts (Lide, 1991-92; Gandini et al, 
1997). Both stereoisomers of nicotine i.e., 1-nicotine and d-nicotine are behaviorally and 
physiologically active (Risner et al, 1988). Nicotine is a tertiary amine (Suzuki and 
Ohshima, 2002) resulting from the combination of two independently synthesized 
moieties, a pyridyl ring derived from nicotinic acid and an N-methyl-pyrollinium salt 
derived from A -^methyl putrescine (Davis et al, 1991). 
Structure of nicotine 
The average cigarette contains approximately 10 mg of nicotine; the range varies 
between 5-15 mg, according to the brand and size of cigarettes. For each cigarette about 1 
mg of nicotine can be absorbed (Gandini et al, 1997; Zenzes, 2000). This toxic alkaloid 
is quickly absorbed through the respiratory tract, mouth mucosa and skin (Gandini et al, 
1997). About 80-90% of the nicotine is metabolized mainly by the liver, but also by the 
kidney and lung (Armitage et al. 1975). On average 72% (range 55-92%) nicotine is 
converted to cotinine (Perkins et al, 1996). Cotinine is a more stable compound than 
nicotine, with a longer half-life of about 20 hours (Zenzes, 2000). Half-life of nicotine is 
138 minutes (Benowitz et al, 1995) or approximately 2 hours (Zenzes, 2000). The 
average peak plasma levels of nicotine range from -30 to 50 ng/ml in cigarette smokers 
and -22 to 30 ng/ml in smokeless tobacco users (Black et al, 2001). 
Sources of nicotine 
This psychoactive substance was isolated from leaves of tobacco plant, Nicotiana 
tabacum in 1828 and is clearly a substance to which the human population at large is 
routinely and continuously exposed. The most important source of nicotine is tobacco 
(Gupta et al, 1996). A large proportion of population uses it by smoking it in pipes, 
cigars or cigarettes or by taking it in unsmoked form as oral and nasal snuff. The most 
common form of tobacco use is cigarette smoking. In India, tobacco is smoked in many 
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ways; the most common is bidi, others being chutta, including reverse smoking, hookah, 
and clay pipe (Gupta et al, 1996). In recent years, the use of nicotine as nasal spray, 
nicotine gum, sublingual tablets, inhalers and transdermal patch has also become 
common. 
Non-smokers are exposed to nicotine through plant material and environmental 
tobacco smoke (ETS). Plant sources other than tobacco have been reported to contain 
varying levels of nicotine (Table 2). Many of such plants are common dietary 
constituents, e.g. eggplant, tomato and green pepper (Castro and Monji, 1986; Sheen, 
1988). These plants are primarily from the family Solanaceae. However, nicotine has a 
wider distribution in the plant kingdom. It has been reported in 12 families and 27 genera. 
Black tea, mcluding regular and decaffeinated brands, and instant teas are also reported to 
contain nicotine (Davis et al, 1991). 
Table 2 
Plants other than Nicotiana that produce nicotine 
Scientific name 
Asclepias syriaca 
Atropa belladonna 
Cannabis sativa 
Carica papaya 
Datura stramonium 
Duboisia hopwoodii 
Duboisia myoporoides 
Equisetum arvense 
Erythrozylon coca 
Lysopersicon esculentum 
Lycopodium (species) 
Mucuna 
Petunia viuolacea 
Sedum acre 
Sempervivum arachnoideum 
Solanum melagena 
Solanum tubersum 
Zinnia elegans 
Common name 
Milkweed 
Deadly nightshade 
Marijuana 
Pawpaw 
Jimson weed 
Pituri 
Corkwood tree 
Field horsetail 
Coca tree 
Tomato 
Club mosses and ground cedars 
Velvet-ban 
Petunia 
Mossy stonecrop 
Hens and chicks 
Egg plant 
Potato 
Garden zinnia 
Adapted from Davis, R.A., Stiles, M.F., Debethizy, J.D. and Reynolds, J.H. (1991) Fd. 
Chem. Toxic. 29: 821-827. 
Either the nicotine containing plants possess the biosynthetic pathway for the 
production of nicotine, or it results from some contamination, perhaps insecticide residue, 
as postulated by Sheen (1988). Biosynthesized nicotine occurs in a number of botanical 
species, but is commonly associated with Nicotiana and other Solanaceae (Davis et ai, 
1991). 
Nicotine has been detected in physiological fluids such as seminal plasma, saliva, 
and urine, of non-smokers, as a result of exposure to ETS (Hoffmann et al, 1985; 
Pacifici et al, 1995). Thus, passive or second-hand or involuntary smoking may also lead 
to nicotine exposure. 
Mode of action of nicotine 
Nicotine is an agonist at nicotinic acetylcholine receptors (nAChRs), which are 
found not only in the central and peripheral nervous systems but also on other cells 
throughout the body (Hallquist et al, 2000). Neuronal and some non-neuronal cells (e.g., 
bronchial epithelial cells, endothelial cells, smooth muscle cells, and skin keratinocytes) 
express nAChRs (Grando et al., 1995; Macklin et al., 1998; Wessler et al., 1999). 
Nicotine binds to its receptors on cell membranes, which leads to activation of multiple 
signal transduction pathways (Arredondo et al., 2001). These receptors modulate release 
of different neurotransmitters, including dopamine, norepinephrine, acetylcholine, 
serotonin, glutamate, 6-endorphin and others (Clarke er a/., 1985; Yu and Wecker, 1994; 
McGehee et al., 1995; White and Levin, 1999)- The smoking addiction results from 
nicotine acting on neuronal acetylcholine receptors in the brain in key regions controlling 
behavior (Minna, 2003). Nicotine shows typical bi-phase actions, both stimulating and 
depressive/inhibitory on various organs (Benowitz, 1988; Gandini et al., 1997). Nicotine 
enhances the experience of pleasure through its effects on the dopaminergic system 
(Swan, 1999a), while its ability to reduce anxiety and tension is mediated through 
stimulation of ACTH and Cortisol; nicotine's ability to enhance task performance may be 
due principally to its action on the cholinergic and noradrenergic pathways (Pomerleau 
and Pomerleau, 1984). Nicotine can act pre-synaptically by stimulating neurotransmitter 
release and post-synaptically by allowing Ca^ "" influx through nAChRs or voltage gated 
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Ca^ "" channels (Picciotto et ai, 2001). The locomotor-stimulating action and the 
reinforcing properties of nicotine are mediated through increasing dopamine release in 
the mesolimbic dopamine system (Stolerman et al, 1995). Nitric oxide (NO) is thought 
to be involved in some of the central effects of nicotine (Pogun et ai, 2000). 
Metabolism of nicotine 
Nicotine delivered in alkaline cigar and pipe smoke, smokeless tobacco and some 
European cigarettes is readily absorbed through the mucosal membranes of the mouth 
and nose, which explains the rapid absorption associated with smokeless tobacco 
(Henningfield, 1995). Cigarette smoke is acidic and must be inhaled to be absorbed 
effectively in the pulmonary alveoli, where absorption is rapid (USDHHS, 1988; 
Henningfield, 1995). After nicotine is absorbed through the lungs by cigarette smoking, it 
undergoes extensive metabolism in humans (Nakajima et al, 2002). Most of the nicotine 
is metabolized to cotinine by C-oxidation. Deficient C-oxidation, a rare phenomenon, is 
associated with a long half-life of nicotine and deficient generation of cotinine (Benowitz 
et al, 1995). Nicotine is mainly metabolized to cotinine by cytochrome P450(CYP)2A6 
(Nakajima et ai, 2002), which is a genetically polymorphic enzyme (Nakajima et ai, 
1996; Messina et al., 1997). It has been found that large inter-individual difference in 
nicotine metabolism are attributed to the genetic polymorphisms of CYP2A6 gene 
(Nakajima et ai, 2002) Besides nicotine inactivation, CYP2A6 is also responsible for 
activating tobacco-related procarcinogens such as nitrosamines (Tyndale et al, 1999). 
Prolong use of nicotine 
People continue to use nicotine despite numerous adverse effects of its use on 
human body. There are multiple reasons for prolong or continued use of nicotine by 
human population: (1) people get addicted to nicotine, and their dependence on nicotine 
force them for its continued use; (2) people get tolerated to nicotine; (3) there is a 
growing number of people who want to quit smoking, such people use nicotine as an aid 
in smoking cessation; (4) there are published benefits of nicotine which encourage people 
for its continued use. 
11 
Nicotine addiction and dependence: WHO and the American Psychiatric 
Association (ASA) classify tobacco dependence as a disease (Nardini et ai, 2001). 
Nicotine dependence has been defined as a common, chronic, relapsing condition (Vainio 
et al, 2001). A large proportion of cigarette smokers develop nicotine dependence, as it 
is highly addictive (USDHHS, 1988; 1994; Schelling 1992; Breslau et al, 1994; ASA, 
1996). One third to one half of occasional cigarette smokers graduate to maladaptive use 
of and to physical dependence on nicotine. Most tobacco-dependent persons never 
achieve lasting abstinence, and half of all smokers die prematurely of tobacco-related 
disease (USDHHS, 1988; 1994; Peto er a/., 1994). 
Nicotine is believed to be the primary component of tobacco that motivates 
continued use (Rossing, 1998). Although nicotine contents in cigarettes have decreased 
over the last 40 years, its addiction drives smokers to maintain blood nicotine levels, 
leading them to compensate by increasing their smoking habit. Smokers self-titrate their 
nicotine levels, so that smokers of lower nicotine cigarettes inhale more (Shields, 2000). 
Thus, nicotine dependent smokers adjust their smoking behavior to maintain peripheral 
and central nicotine levels (Tyndale et al, 1999). Habit-forming actions of nicotine 
appear to be triggered primarily at nicotinic receptors on the cell bodies of dopaminergic 
neurons in the mesolimbic "reward" system of the brain (Rossing, 1998). Nicotine 
increases extracellular dopamine by stimulating the firing of dopaminergic neurons. 
Nicotinic receptors are present in the brain, autonomic ganglia, and neuromuscular 
junction. Neuronal nicotinic acetylcholine receptors, which are located throughout the 
brain, are believed to be most relevant to nicotine addiction (Rossing, 1998). Chronic 
nicotine use results in an increased density of nicotinic receptors in various brain areas, 
and this increase influences dependence on nicotine (Rossing, 1998). Dopamine 
transporter inhibitor anti-depressants (e.g., buproprion) are now used to treat nicotine 
addiction (Hurt et al, 1997). NO is thought to contribute to nicotine addiction since it 
increases nicotine absorption, reduces symptoms of stress and increases post-synaptic 
dopamine level (Vleeming et al, 2002). 
Fagerstrom test is used to differentiate between low, medium and high dependent 
smokers (Heatherton et al, 1991). The reported lifetime prevalence of nicotme 
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dependence is 20% (Breslau et al, 1994). Its addiction is a complex trait (Swan, 1999b) 
and there is a substantial genetic influence on the initiation and maintenance of smoking 
(Sullivan and Kendler, 1999). Twins, adoption and other studies suggest that all stages of 
tobacco use and nicotine dependence are partially under genetic control (Swan, 1999a; 
Cheng et al, 2000; Vainio et al, 2001; Hall et al, 2002). Differences in sensitivities to 
nicotine; the density in nicotine-receptor binding sites; the ability to develop tolerance to 
nicotine; and the extent of self-administration, all are mediated by genes (Swan, 1999a). 
However, environmental factors also play a significant role in initiation and maintenance 
of tobacco use. Nicotine dependence rate varies with age, sex, race, education, and 
marital status (Breslau et al, 1994). Various models have been proposed to explain the 
many possible gene-environment interactions and risk factors for the initiation of 
smoking (Fig. 1). Various effects that are associated with nicotine dependence increase 
the compulsion to smoke by producing positive reinforcement (with the administration of 
nicotine) and withdrawal symptoms (with abstinence) (USDHHS, 1988; Breslau et al, 
1994; Henningfield et al, 1995). Table 3 and 4 depict the diagnostic criteria of the ASA 
for nicotine dependence and withdrawal (ASA, 1994). 
Nicotine tolerance: Tolerance can be defined as reduced magnitude of drug 
effect with repeated exposure (Perkins et al, 1996). Tolerance to various effects of 
nicotine (increases in heart rate, blood pressure, plasma epinephrine and energy 
expenditure) occurs within the range of nicotine levels found in smokers (Fattinger et al, 
1997). The mechanism of acute tolerance to nicotine seems to involve primarily 
desensitization of nicotinic cholinergic receptors (Wonnacott, 1990). Acute tolerance to 
effects of nicotine has been well characterized for electrophysiologic responses in 
cultured cells, release of acetylcholine, dopamine and rubidium from brain synaptosomes, 
and blood pressure, ACTH, corticosterone, prolactin release, locomotor activity and body 
temperature depression in intact animals (Fattinger et al, 1997). In addition to receptor 
desensitization, homeostatic responses may also contribute to acute tolerance, e.g., 
glucocorticoid release with negative feedback is partially responsible for development of 
tolerance to ACTH secretion produced by nicotine (Pauly et al, 1992). 
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Genetic 
• Stress reactivity 
• Cognitive dysfunction 
• Obesity 
• Thrill seeking 
• Nicotine sensitivity and 
metabolism 
4 • 
Environmental 
• Family discord 
• Need for academic, 
and social problem 
solving 
• Constant cultural 
demand for thinness 
(A) 
Initiation 
k J . 
^ smoking 
Metabolism 
Initiation 
I 
Exposure 
Psychopathology 
(B) 
Ethnicity, Gender 
Genetic substrate 
Fig. 1. Smoking initiation (A) Gene-environment interaction model of smoking 
initiation.* (B) Simplified model explaining risk factors for initiation.** 
* Adapted from Swan, G.E. (1999a) Nicotine Tob. Res. 1: S49-S56. 
** Adapted from Swan, G.E. (1999b) Nicotine Tob. Res. 1: S71-S73. 
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Table 3 
Criteria of the American Psychiatric Association for Nicotine 
Dependence Disorder 
Nicotine dependence disorder is a maladaptive pattern of substance use, leading to 
clinically important impairment or distress, as manifested by three or more of the 
following at any time in a 12-month period: 
1. Tolerance, as defined by the need for markedly increased amounts of the 
substance to achieve intoxication or the desired effect, or a markedly diminished 
effect with continued use of the same amount of the substance. 
2. Withdrawal, as manifested by the characteristic withdrawal syndrome for the 
substance, or the taking of the same (or a closely related) substance to relieve or 
avoid withdrawal symptoms. 
3. The substance is often taken in larger amounts or for a longer period than was 
intended. 
4. There is a persistent desire or unsuccessful efforts to cut down or control 
substance use. 
5. A great deal of time is spent in activities necessary to obtain the substance (e.g., 
visiting multiple doctors or driving long distances), use the substance (e.g., chain 
smoking), or recover from its effects. 
6. Important social, occupational, or recreational activities are given up or reduced 
because of substance use. 
7. The substance use is continued despite the knowledge that there is a persistent or 
recurrent physical or physiological problem likely to have been caused or 
exacerbated by the substance (e.g., current cocaine use despite the recognition of 
cocaine-induced depression, or continued drinking despite the recognition that an 
ulcer was made worse by alcohol consumption). 
Adapted from Henningfield, J.E. (1995) N. Engl. J. Med. 333: 1196-1203. 
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Table 4 
Criteria of the American Psychiatric Association for Nicotine 
Withdrawal Disorder 
1. Nicotine is used daily for at least several weeks 
2. There is abrupt cessation of nicotine use, or reduction in the amount of nicotine 
used, followed within 24 hours by four or more of the following symptoms: 
a. Dysphoric or depressed mood 
b. Insomnia 
c. Irritability, frustration or anger 
d. Anxiety 
e. Difficulty in concentrating 
f. Restlessness 
g. Decreased heart rate 
h. Increased appetite or weight gain 
3. The symptoms cause clinically important distress of impairment in social, 
occupational, or other important areas of functioning 
4. The symptoms are not due to a general medical condition and are not better 
accounted for by another mental disorder 
Adapted from Henningfield, J.E. (1995) N. Engl. J. Med. 333: 1196-1203. 
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Acute tolerance to subjective effects, heart rate increase and increased metabolic 
rate has been well described (Porchet et al, 1988; Perkins et al, 1993; Arcavi et al, 
1994). Tolerance is important because tolerance to psychoactive effects contributes to 
nicotine addiction. Acute tolerance influences how reinforcing nicotine self-
administration is at various times of the day during regular tobacco use, and it may 
determine temporal patterns of tobacco use (Benowitz, 1990). Acute tolerance to 
cardiovascular and metabolic effects may have an impact on the potential adverse effects 
of nicotine on the cardiovascular system and the effects of nicotine on body weight 
(Arcavi et al, 1994). 
Nicotine medications: Alternative nicotine delivery systems (ANDS) have been 
designed to provide nicotine without the harmful substances contained in cigarette smoke 
(Kunze et al, 1999). Various forms of NRTs (nicotine replacement therapies) have been 
found to be efficacious and well tolerated for treating patients dependent on tobacco 
(Sims and Fiore, 2002). In contrast to smoking, the use of NRT exposes patients to none 
of the cancer causing chemicals and cardiovascular toxins found in tobacco products and 
also to relatively slower, lower, and less variable plasma concentrations of nicotine 
(Henningfield and Keenan, 1993; Henningfield, 1995; Benowitz and Gourlay, 1997; 
Sims and Fiore, 2002). Thus, the risks of NRT for smokers are small and are substantially 
outweighed by the potential benefits of smoking cessation (Benowitz and Gourlay, 1997). 
NRT is believed to facilitate smoking cessation both by relieving withdrawal symptoms 
and by reducing the physiological reward from smoking; the degree of relief is directly 
related to the dose (USDHHS, 1988; Henningfield, 1995; Benowitz et al, 1998). 
However, the mechanism by which NRT enhances smoking cessation is not completely 
understood (Benowitz et al, 1998). 
The first nicotine medication was a transmucosally delivered product, nicotine 
polacrilex (nicotine gum), approved by the Food & Drug Administration in 1984 (FDA, 
USA). Many reports are available focusing on the use of various nicotine medications, 
e.g., chewing nicotine polacrilex, transdermal nicotine, nasal spray, sublingual tablet, and 
oral inhaler (Henningfield, 1995; Benowitz et al, 1998; Molander and Lunell, 2001). For 
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patients who are highly dependent on nicotine combined therapy using both nicotine 
polacrilex and transdermal nicotine may be used (Henningfield, 1995). 
NRTs may be used in treatment of Alzheimer's disease, panic disorder, 
Parkinson's disease, sleep apnea, and ulcerative colitis (Gothe et al, 1985; Hughes, 1986; 
Newhouse and Hughes, 1991; Srivastava et al, 1991; Fagerstrdm et al, 1994; 
Henningfield, 1995; Tonnessen et al, 2000). Nicotine gum has been shown to be 
effective in reducing post-cessation weight gain (Gross et al, 1995). 
Benefits of nicotine: Tobacco smoking might protect smokers from some 
diseases (Sopori, 2002). Cigarette smokers have a lower incidence and/or severity of 
several diseases (Sopori et al, 1994; Sopori et al, 1998; Sopori, 2002). Most of these 
beneficial effects of cigarette smoking are believed to be associated with the anti-
inflammatory effects of nicotine (Sopori and Kozak, 1998; Sopori, 1998). Nicotine is 
used for the treatment of Tourette's syndrome, ulcerative colitis, endometriosis, 
sarcoidosis, Parkinson's disease, Alzheimer's disease, cutaneous inflammation, 
schizophrenia, and some other neurodegenerative diseases (Perkins et al, 1996; Zins et 
al, 1997; Rossing, 1998; Dursun and Kutcher, 1999; Green et al, 2000; Cormier et al, 
2001; Sopori, 2002). 
Numerous studies, both in animals and humans, have demonstrated that nicotine 
administration results in improved memory, improved performance on attentionally and 
cognitively demanding tasks, decreased errors of omission, improved retention in 
avoidance task and improved learning capacity (White and Levin, 1999; Heishman, 1999; 
Picciotto et al, 2001). Nicotine improves attentiveness and/or cognition not only in 
normal adults (White and Levin, 1999) but also in people with schizophrenia (Levin et 
al, 1996a); Alzheimer's patients (Sahakian et al, 1989; Sopori and Kozak, 1998; White 
and Levin. 1999; Picciotto et al, 2001); adults with attention deficit/hyperactivity 
disorder (ADHD) (Levin et al, 1996b; Kent ei al, 2001). However, if nicotine-addicted 
persons are deprived of nicotine, attentional and cognitive abilities can be impaired 
(Heishman, 1999). 
Nicotine can exert a variety of neuroprotective effects (White and Levin, 1999; 
Garrido et al, 2001). A study shows that in vitro nicotine has radical scavenging 
properties, which might suggest neuroprotective effects (Ferger et al, 1998). The toxic 
properties of nicotine make it useful as an insecticide (Narahashi et al, 2000), which has 
led to its use in agriculture and horticulture. Nicotine use induces relaxation and 
pleasurable feelings and reduces anxiety, anger, and depression (Lyon, 1999). Nicotine is 
an appetite suppressant (White and Levin, 1999); so many people continue to smoke to 
keep their weight under control. Nicotine has been reported to show protective effects on 
hypoxia-induced membrane disintegration and DNA fragmentation of cultured PCI2 
cells (Tohgi et al, 2000) and to reduce glutamate toxicity (Sopori, 2002). 
Adverse effects of nicotine 
Although tobacco smoke contains thousands of chemicals, it has been proposed 
that nicotine is one of the key constituents causing adverse health effects (Benowitz 
1986; 1997a; Benowitz and Gourlay, 1997; Zevin et al, 1998) and that nicotine 
replacement products may be harmful (Grady, 1998). It is generally agreed that nicotine 
plays a major role in mediating the pharmacological, biochemical, psychological, and 
other effects of cigarette smoking (Dursun and Kutcher, 1999). The use of nicotine-
containing tobacco products has been associated with immunomodulation and an increase 
in specific diseases, such as respiratory tract infections, chronic airway disease, asthma in 
children exposed to second-hand smoke, allergies, and lung and other cancers (Hallquist 
et al, 2000). Nicotine is a neuroteratogen, which mimics the actions of the endogenous 
transmitter acetylcholine (Trauth et al, 2000). Nicotine, acting through the nAChRs 
expressed by non-neuronal cells has recently emerged as a candidate for the major 
pathogenic factor in tobacco-related morbidity because it exhibits a regulatory role in 
biological processes which are intimately connected with each other, including cell 
growth, motility, and differentiation (Heeschen et al, 2001). Exposure to nicotine, and 
tobacco products alters the expression of the cell cycle and cell differentiation genes, 
such as cyclin Dl, which is implicated in the induction and control of mitosis (Hunter and 
Pmes, 1994); p2r='^', which plays an important role during cell differentiation (Poluha et 
al, 1997); p53, which affects the cell cycle arrest (Lane and Benchimol, 1990); Ki-67 
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and PCNA, both of which are expressed during cell cycle (MacCallum and Hall, 1999; 
Tsurimoto, 1999); thus, leading to various abnormalities (Arredondo et al, 2001). 
Nicotine and DNA: Studies have suggested that nicotine may regulate DNA 
synthesis, but results have been inconclusive and contradictory. While some studies have 
demonstrated that nicotine can stimulate DNA synthesis (Thyberg, 1986; Zimmerman 
and McGaechie, 1987; Schuller, 1989; Boutherin-Falson and Blaes, 1990; Ramp et al, 
1991; Waggoner and Wang, 1994), others have reported that nicotine does not stimulate 
or even decreases DNA synthesis (Booyse et al, 1981b; Tomek et al, 1994). Some 
investigations associate nicotine with cell loss and desquamation (Zimmerman and 
McGaechie, 1985), while others demonstrate it to be mitogenic and cell proliferative 
(Nylen et al, 1993; Waggoner and Wang, 1994; Villablanca, 1998; Cucina et al, 1999; 
2000). Some reports show that nicotine effects on cell proliferation are biphasic with 
toxic, antiproliferative effects at high levels of nicotine and stimulatory effects at very 
low levels (Walker et al, 2001). Few studies show that nicotine does not damage DNA 
(Altmann et al, 1984) while others show that it can cause DNA damage/degradation 
(Kozlovskis-Wade et al, 1998; Pryor et al, 1998); it has been reported to induce 
intemucleosomal DNA cleavage in human myelogenous leukemic cell lines (Yoshida et 
al, 1998). 
Nicotine toxicity: Nicotine is a toxic component of cigarettes and smokeless 
tobacco (Mayhan and Sharpe, 1998a). Its inhalation exerts direct toxic effect on the 
respiratory tissue (Zia et al, 1997). It shows cytotoxic effect on endothelial cells, which 
is associated with inhibition of DNA synthesis and direct cell kill (Villablanca, 1998). 
Nicotine and NNK promote the development of oxidative stress by cigarette smoke 
(Baskarin et al, 1994; Cai and Harrison, 2000). It is not only toxic by itself; but also 
enhances toxicity of many other compounds. CYP2E1 is an ethanol- and drug-
metabolizing enzyme that can also activate procarcinogens and hepatotoxins and generate 
reactive oxygen species; it has been implicated in the pathogenesis of liver diseases and 
cancer. Nicotine increases CYP2E1 at very low doses and may enhance CYP2E1-related 
toxicity in smokers, passive smokers and people treated with nicotine (e.g. smokers, 
patients with Alzheimer's disease, ulcerative colitis or Parkinson's disease) (Micu et al. 
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2003). Arecoline, a major areca nut alkaloid, is reported to cause oral cancer. Nicotine 
acts synergistically on the arecoline-induced cytotoxicity (Chang et ai, 2001). Nicotine 
enhances the damage of DNA by oxygen-free radicals (Kozlovskis-Wade et ai, 1998). 
Cytotoxic neutrophil derived oxygen radicals have been implicated in the pathogenesis of 
a variety of cardiovascular, pulmonary, and neoplastic disorders. Nicotine-induced 
exacerbation of neutrophil superoxide anion production enhances the risk of such 
disorders in smokers (Jay et ai, 1986). Nicotine also enhances genotoxicity and tissue 
damage caused by neutrophil activation by enhancing the yields of HOCl-modified 
nucleosides, which may be important in the pathophysiology of human diseases 
associated with tobacco habits (Masuda et ai, 2001; Suzuki and Oshima, 2002). Nicotine 
potentiates the lethal action of certain sudden infant death syndrome (SIDS) cases 
associated bacterial toxins (Sayers et ai, 1995). Nicotine increases oxidative stress; it 
also sensitizes cells to genotoxic/xenobiotic stresses by enhancing the ability of 
deoxycholate to activate the 153 kD growth arrest and DNA damage promoter and the 
xenobiotic response element (Crowley-Weber et al, 2003). Nicotine, via signal 
transduction pathways, leads to enhanced levels of intracellular calcium release, resulting 
in cytotoxicity, cell damage, and eventually cell death, a mechanism involved in nicotine-
induced pancreatic injury and other damages (Zia et ai, 1997; Chowdhury et ai, 2002). 
Nicotine can also alter the cell death pathway by reducing the level of intracellular ATP, 
which may contribute to cigarette smoke-induced tissue restriction (Sugano and Ito, 
2000). Animal studies show that it also enhances the effect of certain carcinogens such as 
the nitrosamines (Chen et al., 1994). 
Nicotine and cardiovascular system: Nicotine exposure contributes to 
cardiovascular pathology (atherogenesis, vascular dysfunction, accelerated coronary 
artery disease, acute cardiac ischemic events, hypertension and atherosclerosis) 
(Benowitz, 1997a; 1997b; Villablanca, 1998; Albaugh et ai, 2001; Hakki et al., 2002). 
Addictive cardiovascular effects of nicotine could contribute to arrhythmias and sudden 
death in patients with coronary heart disease (Benowitz et ai, 1986). It affects 
cardiovascular function through the release of neurotransmitters or vasoactive substances 
(Miller et ai, 1998), by hemodynamic consequences of sympathetic neural stimulation 
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(Benowitz and Gourlay, 1997, Benowitz, 1997b), by inhibiting apoptosis in endothelial 
cells (Hakki et al, 2002), or through proliferative effects (Villablanca, 1998). It is well 
known to enhance vasoconstriction by impairing endothelium-dependent and 
endothelium-independent vasodilation (Gerzanich et al, 2001). Nicotine induces 
plasminogen activator inhibitor-I production by human brain endothelial cells, leading to 
increased stroke risk (Zidovetzki et al, 1999). It also shows addictive effects on heart-
rate and pressure-rate product (Benowitz et al, 1986). Nicotine impairs vascular function 
(Lin et al, 1992) and brings changes in vascular endothelium (Villablanca, 1998). It 
causes morphological changes in endothelial cells, increased endothelial cell death, and 
enhanced permeability to atherogenic macromolecules (Lin et al, 1992; Cucina et al, 
2000, Tithofl et al, 2001; Conklin et al, 2002). Nicotine induces changes in expression 
of various atherosclerosis-related genes in endothelial cells including endothelial nitric 
oxide synthase, angiotensin-I converting enzyme, tissue-type plasminogen activator, 
platelet-derived growth factor and basic fibroblast growth factor (Cucina et al, 1999; 
2000; Conklin et al, 2001). Nicotine shows a bimodal response, at concentrations lower 
than that obtained in blood after smoking, it stimulates endothelial cells DNA synthesis 
and proliferation (Villablanca, 1998), while at higher concentrations it causes cytotoxicity 
and endothelial cell growth retardation (Villablanca, 1998; Albaugh et al, 2001). 
Nicotine shows deleterious effects on endothelial function in skin vasculature (Black et 
al, 2001). It also decreases skin temperature reflecting cutaneous vasoconstriction 
(Benowitz era/., 1986). 
Nicotine and reproduction: Chronic exposure to nicotine and NNK in pregnant 
women increases the susceptibilities of the infants for the development of pediatric lung 
disorders such as bronchopulmonary dysplasia, cystic fibrosis, SEDS, asthma, and small 
cell lung carcinoma (Schuller et al. 2000). Prenatal nicotine exposure is known to 
suppress fetal growth, to adversely affect the developing fetal CNS, to produce brain 
damage, to alter synaptic function, and to cause behavioral anomalies (Pennington et al, 
1994; Trauth et al, 2000). Nicotine effects on the brain may be involved in the 
pathophysiology of SIDS (Dempsey and Benowitz, 2001). Gestational nicotine exposure 
elicits inappropnate expression of genes involved in differentiation and apoptosis, 
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leading to mitotic arrest and cell death (Sopori, 1998). Nicotine may also lead to delay in 
meiotic maturation and meiotic arrest in the oocytes (Zenzes, 2000). Studies show that 
nicotine exposure adversely affects maternal and fetal cardiovascular systems (Dempsey 
and Benowitz, 2001). Cardiovascular effects of nicotine resulting in reduced blood flow 
to the placenta (uteroplacental insufficiency) are the predominant mechanisms of the 
reproductive toxicity of cigarette smoking during pregnancy (Dempsey and Benowitz, 
2001). Exposure of nicotine and other tobacco alkaloids may result in impaired placental 
growth, disorder in the placental vascular architecture and placental circulation, and 
small-for-date babies (Gocze and Freeman, 2000). Cytotoxic effects of nicotine reduce 
the fertilization, implantation, and early human development (Gocze and Freeman, 2000). 
Catecholamine systems are particularly sensitive to prenatal nicotine exposure (Oliff and 
Gallardo, 1999). It may contribute to fetal growth restriction by interfering with the 
activity of amino acid transporters that are necessary to maintain the nutrient gradients 
associated with normal fetal growth (Pastrakuljic et al., 2000). It also inhibits 
progesterone synthesis (Gocze and Freeman, 2000). 
Nicotine damages in adolescence: Similar to prenatal brain, the adolescent brain 
is also vulnerable to nicotine. However, effects on gene expression and on indices of cell 
number and size are smaller in adolescent than in gestational nicotine exposure. Its 
exposure leads to reduction in DNA content (which reflects either interference with cell 
proliferation, or necrotic/apoptotic cell loss) as well as alterations in the characteristics of 
remaining ells (increased protein/DNA ratio) (Trauth et al., 2000). Development of 
nicotine addiction typically occurs during adolescence; nicotine addiction has thus been 
termed a pediatric disease (Heishman et al., 1997). 
Nicotine and inhibition of apoptosis: Nicotine has been reported to inhibit 
apoptosis in different cell lines (Zenzes, 2000). Inhibition of apoptosis by nicotine is an 
important factor in the development of various pathological conditions, e.g., cancer, 
tumor promotion, cardiovascular disease, atherogenesis, and in the alteration of immune 
response to infections (Maneckjee and Minna, 1994). Suppression of apoptosis by 
nicotine also contributes to prolongation of neutrophil survival and their accumulation in 
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the lung, which is implicated in the pathogenesis of pulmonary emphysema and chronic 
bronchitis associated with cigarette smoking (Aoshiba et al, 1996). 
Nicotine and oral cavity: Nicotine affects defensive functions of neutrophils by 
inhibiting their bactericidal activities against oral pathogens, and their ability to produce 
microbicidal molecules. Nicotine also inhibits production of interleukin-1 beta by 
monocytes. Inhibition of aerobic antimicrobial functions of neutrophils and monocytes by 
nicotine may alter the microbial ecology of the oral cavity, and this might be one 
mechanism by which nicotine compromises the oral health of users of tobacco products 
(Pabst et al., 1995). Nicotine may also affect the periodontal environment by the 
excitation of apoptosis by nicotine on polymorphonuclear cells, which are the first line 
defensive cells. The premature death of defensive cells could promote infection, 
inflammation and concomitant disease (Mariggio et al, 2001) 
Nicotine and lipid metabolism: Animal studies show that oral administration of 
nicotine leads to elevated levels of fasting serum glucose, triglycerides, total cholesterol, 
and LDL-cholesterol. Endothelial cells in aortic arch of such animals show increased 
formation of microvilli, projections on cell surface (Booyse et al, 1981a). Oral nicotine 
consumption decreases HDL/total cholesterol ratio through enhancing lipolytic 
conversion of VLDL to LDL (Cluette et al, 1986; Sun et al, 2001). The diminished 
removal of LDL would increase their deposition in the arterial wall (Hojnacki et al, 
1986). Nicotine has been reported to increase lipolysis in heavy smokers (Hellerstein et 
al, 1994) via local release of norepinephrine (Fattinger et al, 1997). It increases the 
synthesis of triglyceride-rich lipoprotein (Ashakumary and Vijayammal, 1997) exerting 
hyperlipidemic effect (Sun et al, 2001). Nicotine also releases free fatty acids from 
triglycerides in adipose tissue (Ilebekk et al, 1975). 
Contradictions and adverse effects of NRTs: Studies have demonstrated that 
nicotine replacement products may be harmful (Grady, 1998; Zins et al, 1997) as some 
patients show hypersensitivity or allergy to it. Common side effects of nicotine 
medications include jaw fatigue and soreness, hiccupping and burping, nausea, abnormal 
dreams, dizziness, headache, agitation, and loss of appetite (Henningfield, 1995; Smith 
and Winters, 1995; White and Levin, 1999). Some of these side effects have been 
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observed not only in patients, but also in their caregivers (White and Levin, 1999) 
Besides these common side effects, other rare effects include anxiety, transient elevation 
in blood pressure, blurred vision, and slurred speech (White and Levin, 1999). Nicotine 
skin patch treatment may lead to skin reactions such as mild pruritus and edema, and 
sleep disturbances (Henningfield, 1995; White and Levin, 1999). Nicotine delivered by 
transdermal systems and nicotine polacnlex may cause cardiovascular and endocnne 
effects (Henningfield, 1995) Use of nasal spray shows side effects such as imtation in 
the nose and throat, runny nose, watenng eyes, and coughing (Heishman et al, 1997) 
Vanous methods of nicotine cessation are often met with a high-rate of treatment failure 
or relapse. The actual rate of abstinence using NRT is generally only 25% (Heishman et 
al, 1997) In a study, as much as 65% of subjects using patch systems were relapsed 
(Smith and Winters, 1995) 
Most of the NRT products, i.e., chewing gum, nasal spray, and inhaler, involve 
absorption of nicotine through the mucosa. Unfortunately, little is known about the direct 
effects of nicotine on the mucosal epithelium, and the safety of NRT has yet to be 
determined (Arredondo et al, 2001). More research is also needed to clanfy the questions 
regarding the ideal duration of the therapy (Sims and Fiore, 2002). 
Nicotine gum and patches have been approved for over-the-counter sale in the 
United States (Benowitz and Gourlay, 1997). Wider availability of NRT may lead to 
initiation of its addiction by children and others not using tobacco products (Sims and 
Fiore, 2002) Moreover, there are no published studies of the nsks and benefits of 
nicotine therapy in young patients (Henningfield, 1995). Patients with multiple 
psychiatnc diagnoses warrant particularly careful monitonng dunng nicotine medication 
(Henningfield, 1995) No studies have examined smoking cessation programs for chronic 
patients with schizophrenia (Lyon, 1999) Smokers with cardiovascular diseases are 
advised to seek physician counseling before using nicotine products, but information 
regarding the safety of these products in such patients is not readily available to most 
physicians (Benowitz and Gourlay, 1997). The safety and efficacy of NRT dunng 
pregnancy have not been well studied (Dempsey and Benowitz, 2001) However, 
intermittent formulations of NRT (gum, spray, inhaler) are preferred because the total 
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dose of nicotine delivered to the fetus will be less than with continuous-use formulations 
(transdermal patch) (Dempsey and Benowitz, 2001). Considering the uncertainties over 
the safety of NRT in pregnant women, nicotine polacrilex has been accorded Pregnancy 
Category C, which means "risk cannot be ruled out" and transdermal systems have been 
accorded Pregnancy Category D, which means "positive evidence of risk", by the FDA 
(Henningfield, 1995). 
Other effects of nicotine: 
> Nicotine via nAChR stimulates angiogenesis in a number of milieus, including 
inflammation, ischemia, tumor and atherosclerosis (Heeschen et al, 2002). It 
enhances vascularization and thus accelerates tumor growth and atherosclerosis 
(Heeschen er a/., 2001). 
> Nicotine is an appetite-suppressant (White and Levin, 1999). Its exposure results in 
weight-loss, which is associated with an increase in hypothalamic cholecystokinin, a 
satiety neuropeptide (Comings et al., 2001). 
> Perinatal administration of nicotine produces a broad spectrum of effects on brain 
including inhibition of DNA synthesis, altered ornithine carboxylase activity, altered 
neurotransmitter function, and significant alterations in cortical morphogenesis. 
(McFarland et al. 1991; Oliff and Gallardo, 1999). 
> Nicotine affects primary human bone cells (Walker et al., 2001). It damages alveolar 
bone and inhibits collagen synthesis and alkaline phosphatase activity in osteoblast-
like cells (Ramp et al, 1991). 
> Nicotine induces alterations in the structure and function of keratinocyte nAChRs 
responsible for the physiologic regulation of the cell cycle by cytotransmitter 
acetylcholine. This may lead to precancerous lesions in tobacco users (Arredondo et 
al., 2001). 
> Animal studies have shown that nicotine affects locomotor activity, muscle reflex 
tone, body temperature, heart rate, respiration, salivation, electrocortical indices of 
sleep and arousal, and at high doses, causes convulsions (Marks et al., 1989; Dursun 
and Kutcher, 1999). 
> Nicotine increases the chances of gastric ulcers (Ogle, 1999). 
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> Nicotine acts as a potent aversive stimulant (Dursun and Kutcher, 1999). 
Nicotine and immune response 
Nicotine is an important immunotoxic component within cigarette smoke and 
chronic treatment impairs both the innate, and adaptive immune responses (Sopori et ai, 
1998; Sopori, 2002). It has been shown to alter immune responses by decreasing 
inflammation, decreasing the antibody-forming cell response of splenocytes, decreasing 
T-cell-receptor-mediated signaling, and decreasing proliferation of peripheral blood 
mononuclear cells (Hallquist et al., 2000). Nicotinic acetylcholine receptors are present 
on immune cells (Hallquist et ai, 2000). There is increasing evidence that chronic 
nicotine treatment leads to inhibition of the antibody response indicating that nicotine is a 
major immunosuppressive component in cigarette smoke (Sopori et ai, 1993; 1994; 
1998; Geng et ai, 1995; Sopori and Kozak, 1998; Sopori, 2002), affecting the function of 
both T and B cells (Sopori, 1998). Nicotine-induced immunosuppression may result from 
its direct effect on lymphocytes, indirectly through its effects on the neuroendocrine 
system, or both (Sopori and Kozak, 1998). Nicotine induces functional unresponsiveness 
(anergy) in T cells, a condition in which antigen-specific T cells fail to respond to an 
antigen (Sopori and Kozak 1998). Nicotine-induced T cell anergy may arise through its 
effects on the antigen-mediated signal transduction pathway leading to partial activation 
and arrest of T cells in the Go/Gl phase of the cell cycle (Geng et al 1995; 1996). This T 
cell anergy may contribute to the immunosuppressive and anti-inflammatory properties of 
cigarette smoke and/or nicotine. 
Chronic exposure to nicotine inhibits the antibody-forming cell (AFC) response 
(Sopori et al., 1998), and this immunosuppression is related to impairment of antigen-
mediated signaling in T cells (Geng et ai, 1995; 1996; Sopori et ai, 1998). T cells from 
chronically nicotine-treated animals have depleted IP3-sensitive intracellular Ca^ "" stores 
(Sopori, 1998; Sopori and Kozak, 1998), which impair the cytoplasm-nucleus 
communication, leading to the loss of T-cell function (Sopori, 1998). The ability of 
smokers to resist infections including HIV-1 may be adversely affected, because 
exposure to cigarette smoke/nicotine can lead to T cell anergy (Sopori and Kozak, 1998). 
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Nicotine is absorbed quickly through the pulmonary capillary blood flow. It 
readily crosses the blood brain barrier and is a classical sympathoadrenal stimulant 
(Sopori and Kozak, 1998). It has been shown to produce a dose-dependent increase in 
cerebral glucose uptake indicating increased brain metabolic activity. There are high 
affinity nicotine-binding sites in the hypothalamus (London et al, 1985). It is a potent 
stimulator of hypothalamic-pituitary-adrenal (HPA) axis resulting in the rapid secretion 
of ACTH. Nicotine also increases the concentration of norepinephrine and epinephrine in 
plasma (Pomerleau et al, 1983; Sopori and Kozak, 1998). Both ACTH and 
catecholamines have been shown to inhibit the immune response. Thus, the HPA axis 
potentially contributes to nicotine-induced immunosuppression (Sopori and Kozak, 
1998). 
Nicotine treatment/exposure is also associated with inhibition of pro-
inflammatory cytokines IL-1 and TNF-a production from colonic mucosa (Sopori and 
Kozak, 1998; Sopori, 1998). These pro-inflammatory cytokines are known to play an 
important role in clearing infections from the body (Balkwill, 1993; Marrack and 
Kappler, 1994). This accounts for the higher susceptibility of smokers to infections but a 
lower frequency of some autoimmune diseases (Sopori, 1998). 
Figure 2 summarizes the overall mechanism by which cigarette smoke or nicotine 
affects the immune system. 
Anti-inflammatory properties of nicotine: Inflammation is a double-edged 
sword. Although unregulated or excessive inflammation can be life threatening by 
damaging healthy tissue leading to septic shock or autoimmunity, adequate inflammation 
is required for the development of immune responses, clearance of pathogens and dead 
tissues from the infection site and recovery from tissue injuries (Sopori et al, 1998; 
Sopori, 2002). Cigarette smokers have lower incidence of several inflammatory diseases 
and, compared with non-smokers, smokers have slower and less satisfactory healing of 
wounds that result from trauma, disease or surgical procedures (Silverstein, 1992). 
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Fig. 2. An over-simplified model by which cigarette smoke/ nicotine could affect the 
immune system. 
Adapted from Sopori, M. L. and Kozak, W. (1998) J. Neuroimmunol. 83: 148-
156. 
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Although nicotine has been reported as an anti-inflammatory agent (Sopon et al, 
1998) and it might moderate the seventy of some inflammatory diseases (Vainio et al, 
2001, Sopon, 2002), it shows bipolar effects in inflammatory diseases. This is shown by 
the differential responses of two inflammatory bowel diseases - ulcerative colitis and 
Crohn's disease to nicotine in expenmental models of these diseases While ulcerative 
colitis is rare among smokers, Crohn's disease is 3-5 times more prevalent (Sopon, 
2002) 
By inhibiting inflammation, nicotine appears to increase chances of infections. It 
has been reported to stimulate viral infection (Sopon et al, 1998). Enhanced replication 
of influenza virus and Legionella pneumophila (a causative agent of pneumonia) has been 
observed in the lungs of nicotine-treated animals and AM cell lines, respectively (Sopon, 
2002) 
Free radicals 
A free radical is a highly reactive chemical species that contains one or more 
unpaired electrons and is capable of independent existence. Free radicals can be 
positively charged, or negatively charged, or electncally neutral. They have short half-
lives and low steady state concentrations (Freeman, 1984; Halhwell and Guttendge, 
1984, 1989, Cadenas, 1989) They can be formed by hemolytic fission of a covalent bond 
(von Sonntag, 1987b), or by the loss/addition of a single electron from/to a normal 
molecule The most important free radicals in biological systems are denvatives of 
oxygen known as reactive oxygen species (ROS), which include oxygen-centered 
radicals such as superoxide anion (O2'") and hydroxyl radical (*OH) as well as non-
radical denvatives of oxygen, such as hydrogen peroxide (H2O2), singlet oxygen ('O2), 
hypochlorous acid (HOCl) and ozone (O3) 
In living cells, ROS are produced continuously dunng normal aerobic metabolism 
(Halhwell and Aruoma, 1991) as well as in many pathologic conditions such as tissue 
ischemia, cancer, inflammation and degenerative diseases (Halhwell and Guttendge, 
1984, Vuilaume, 1987) The autooxidation of certain small cytoplasmic molecules such 
as catecholamine, flavins and the activity of some enzymes (xanthine oxidase and 
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aldehyde dehydrogenase) have been known to produce ROS, in vivo (Fridovich, 1983). 
The metabolism of arachidonic acid and respiratory burst from phagocytes also give rise 
to ROS (Halliwell and Gutteridge, 1989). Besides these endogenous sources, ROS are 
also generated by a number of exogenous sources such as inhaled smoke, polluted air, 
certain ingested food and a variety of other carcinogens. The low wavelength ionizing 
radiation (e.g. y ^"d X-ray) and ultraviolet (UV) light are also important exogenous 
sources of ROS (Davies, 1987; Epe, 1991). Various sources of pathogenic ROS are 
summarized in Table 5. 
Superoxide anion radical: Superoxide anion is an important free radical. It is 
resulted from one electron reduction of oxygen (Florence, 1990; Harris, 1992). It is 
formed in all aerobic organisms. It is formed in normal metabolism as well as through the 
action of many drugs, poisons and radiation. Sources of superoxide in injured tissues 
include xanthine oxidase (Granger et al, 1981; Chambers et al., 1985; McCord, 1985; 
Hearse et al., 1986), mitochondria (Boveris et al, 1976; Turrens and Boveris, 1980; 
Turrens et al., 1982), and neutrophils (Dahinder et al., 1983). The superoxide anion 
radical (O2") is considered to be a highly toxic entity in many biological systems 
(Oberly, 1982; Rotelio, 1986; Fridovich, 1986; von Sonntag, 1987b; Harman, 1993). 
Systems generating Oz'" have been observed to kill bacteria, inactivate viruses, damage 
enzymes and membranes, and destroy animal cells in culture (Fridovich, 1978; Halliwell, 
1981). It is involved in DNA damage, phagocytosis, ageing, cancer etc. A number of 
biologically relevant molecules such as epinephrine (McCord and Fridovich, 1969), 
bilirubin (Robertson and Fridovich, 1982), biliverdin (Galliani et al., 1984) also react 
with O2'". Superoxide dismutases (SODs) are the metalloenzymes that catalyze the 
dismutation of superoxide ions into oxygen and hydrogen peroxide (Halliwell, 1994). 
Free radicals in tobacco: Tobacco smoke contains thousands of compounds, 
many of which are oxidants, pro-oxidants, capable of producing free radicals and 
enhancing the oxidative stress in vivo (Kodama et al., 1997; Pourcelot et al., 1999; 
Kocyigit et al., 2001). Both the gas and tar phases of cigarette smoke are well known 
sources of free radicals (Asami et al., 1996; Yoshie and Ohshima, 1997; Hecht, 1999). 
31 
Table 5 
Sources of pathogenic reactive oxygen species 
Endogenous 
> Phagocytic cells stimulated by tumor promoters through: 
• Protein kinase C activation (TPA, mezerein, RPA, teleocidin, 
thapsigargin) 
• Phosphatase inhibition (okadaic acid, palytoxin) 
<• Unknown mechanism (Ni3S2, NiS2, NiS, CdS, CaCr04) 
> Non-phagocytic cells (epidermal keratinocytes, HeLa, MRCS, lOTl/2 and 
others) 
• Treated with tumor promoters 
• Metabolizing complete carcinogens (PAHs, nitro- and amino-
polyaromatics, diethylstilbestrol (DES), metals (Cr, Ni, Hg, Cu) 
> Quinone-semiquinone redox cycling 
> Induction of pro-oxidant enzymes (e.g., xanthine oxidase) 
> Inhibition of antioxidant enzymes 
> Induction of fatty acid and CoA oxidases by peroxisome proliferaters 
> Ischemia/ reperfusion 
Exogenous 
> Ionizing radiations (y, X-ray, ' 'H, U V ) 
> Cigarette smoke 
> Chewing betel nuts 
> Ozone 
> Quinone antibiotics 
> Chemotherapeutic agents 
> Pesticides 
Adapted from Frenkel, K. (1992) Pharmacol. Ther. 53: 127-166. 
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Each puff of a tobacco contains lO"^  oxidant in the tar phase and 10 in the gas 
phase (Kocyigit et al, 2001). The gas phase contains nitric oxide and peroxynitrite. 
Quinones, semiquinones and hydroquinones are present in cigarette tar (Pourcelot et al, 
1999; Hecht, 1999). These components of tar phase can readily form Oi' (Yoshie and 
Ohshima 1997; Pourcelot et al, 1999). Superoxide dismutase converts O'a" into H2O2, 
which in presence of ferrous ions give rise to the highly toxic *0H radical by the Haber-
Weiss reaction (Asami et al, 1996; Pourcelot et al, 1999; Hecht, 1999). Peroxynitrite is 
also toxic and can also generate *0H radicals (Pourcelot et al, 1999). 
Nicotine and free radicals: Literature shows uncertainty about the production of 
ROS by nicotine (Pryor et al, 1998). Many contradictory reports are available regarding 
the effects of nicotine on free radicals generation/scavenging. On one hand, reports show 
that nicotine administration results in oxidative stress by inducing generation of free 
radicals in the periphery and central nervous system. On the other hand, there are 
evidences suggesting that nicotine may have antioxidant properties in the central nervous 
system (Newman et al, 2002). While some reports show that nicotine induces neutrophil 
superoxide production, (Jay et al, 1986) others show that nicotine inhibits uptake of 
oxygen by neutrophils and interferes with the production of oxygen radicals (O2'" and 
H2O2) by these cells (Pabst et al, 1995). Another study demonstrates that nicotine has 
radical scavenging properties, in a cell-free in vitro system nicotine reduced hydroxyl 
radicals' levels (Ferger et al, 1998). Animal studies also show preventive effects of 
nicotine on 'OH generation (Obata et al, 2002). Srivastava et al (1989) explain nicotine 
as an inhibitor of oxygen-free radical production. Cormier et al (2001) have reported that 
nicotine interacts with complex I of the brain mitochondrial respiratory chain and 
decreases ROS generation. 
Contrary to these studies, many studies have shown that nicotine may produce its 
effects via the production of oxygen radicals (Murohara et al, 1994; Mayhan and Sharpe, 
1998a; 1998b; Kurahashi et al, 2001; Chong et al, 2002). It has been reported that 
nicotine impairs dilatation of arterioles via an increase in the synthesis/release of oxygen-
derived free radicals (particulariy O2'") (Mayhan and Sharpe, 1998b; Mayhan and Sharpe, 
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1999; Mayhan et al, 1999; Qin et ai, 2003). A synergistic effect has been reported 
between polyphenols, the main source of O2'" and H2O2 in cigarette smoke, and nicotine 
(Kodama et al, 1997). It also stimulates the production/release of NO (Fedele et ai, 
1998; Smith et ai, 1998; Si and Lee, 2001;Vleeming et ai, 2002), which contributes to 
nicotine addiction (Vleeming et ai, 2002) and is involved in some of the central effects 
of nicotine (Pogun et al, 2000). 
Oxidative DNA damage 
Oxidative stress results either due to over production of ROS or inadequate 
antioxidant defences (Sies, 1991). Oxidative DNA damage is produced when reactive 
oxygen species are generated in cells by normal aerobic metabolism or by exogenous 
sources such as ionizing radiation or carcinogenic compounds, which may be implicated 
in mutagenesis, carcinogenesis and aging (Halliwell and Gutteridge, 1990). The 
endogenous reactions that are likely to contribute to ongoing DNA damage are oxidation, 
methylation, depurination and deamination (Totter, 1980). The attack by ROS upon DNA 
produces a multiplicity of different products such as a range of specifically oxidized 
purines, pyrimidines, abasic sites, alkali labile sites, chain breaks and DNA-protein cross-
links (Breen and Murphy, 1995; Cadet et ai, 1997). The chemistry of DNA damage by 
several ROS has been well characterized in vitro (von Sonntag, 1987b). 
Occurrence in cigarette smoke of toxic oxygen reactive species, i.e., O2*", H2O2 
and 'OH has been widely demonstrated (Pryor et ai, 1998; Pourcelot et al, 1999; Hecht, 
1999). These cause pro-oxidant/antioxidant imbalance, leading to oxidative stress. 
Accumulated oxidative stress induces mitochondrial and nuclear DNA damage (Zenzes, 
2000). ROS generated from cigarette smoke are thought to play an important role in 
cigarette carcinogenesis (Asami et ai, 1996) Radicals in cigarette tar are assumed to 
bind, perhaps covalently to DNA and to produce DNA nicks (Hecht, 1999; Zenzes, 
2000). Studies have demonstrated that cigarette smoke causes single strand breaks and 
the formation of modified bases in the DNA (Asami et ai, 1996; Yoshie and Ohshima, 
1997). It has been shown that NO in the gas phase acts synergistically with cigarette tar 
to cause DNA-single-strand breakage in pBR322 plasmid DNA (Hecht, 1999). It is 
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suggested that peroxynitrite generated from NO and O2*", might be involved in DNA 
damage and oxidative stress (Yoshie and Ohshima, 1997; Muller et ai, 1997). 
Experiments in vitro demonstrate that the gas phase of cigarette smoke causes lipid 
peroxidation of human blood plasma, which is prevented by the addition of ascorbic acid 
(Frei et ai, 1991). Literature has demonstrated moderately increased levels of 8-
oxodeoxyguanosine, a miscoding adduct, in DNA from smokers' lungs, leukocytes, and 
sperm. Increased urinary excretion of 8-hydroxydeoxyguanosine has also been noted 
(Hecht, 1999). Nicotine has also been reported to show oxidative damage on biological 
systems, both mitochondria and microsomes are intracellular targets for nicotine- induced 
organ toxicity (Bhagwat et ai, 1998; Helen et al, 1999). 
Antioxidant defences 
Aerobic organisms have potent antioxidant defences, which are capable of 
scavenging free radicals by preventing their formation, intercepting them from further 
activity, or participating in repair of damage caused by them. It is widely believed that a 
proper balance between free radicals and antioxidants is required for the health of an 
organism (Rautalahti and Huttunen, 1994). There may be enzymatic or non-enzymatic 
antioxidant defences. Enzymatic antioxidant defences include superoxide dismutase 
against 02*~ (Fridovich, 1989), catalase (Amstad et al, 1991) and glutathione peroxidase 
(Singh et al, 1994) against H2O2. Vitamin E (alpha-tocopherol), vitamin C (ascorbic 
acid) and carotenoids are important non-enzymatic antioxidants (Packer et al, 1979; Som 
etal, 1983). 
Studies have shown that tobacco smoke can alter activities of antioxidative 
enzymes such as copper-zinc superoxide dismutase, glutathione peroxidase and catalase 
(Gupta et al. 1988; Duthie and Wahle, 1991; Zhou et al, 2000). Some studies show 
increase in the activities of these enzymes (Sohn et al, 1993) while other show decrease 
in their activities (Gupta et al, 1988), as a result of cigarette smoke exposure. A recent 
study concludes that tobacco smoke affects the plasma concentration of trace elements, 
which are essential components of antioxidative enzymes, and thus, may alter antioxidant 
enzyme activities (Kocyigit et al, 2001). 
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Cancer 
Carcinogenesis is the malignant transformation of a cell or group of cells (Farber 
and Cameron, 1980; Potter, 1983; Farber, 1984). It is a complex process driven by the 
accumulation of DNA changes within a population of cells, and is typically broken into 
three stages - initiation, promotion, and progression (Christiani, 2000). These heritable 
genomic alterations, called mutations, result in phenotypic changes that manifest as 
neoplastic growth. Initiation refers to the fixed genetic change occurring within one cell 
that confers a growth advantage. This initiated cell then undergoes cloned expansion 
during the promotion stage. During this period, there may be further accumulation of 
mutations and growth of the emerging cell population becomes unregulated. The final 
phase of cancer development is termed progression, and induces additional genetic 
changes that render the tumor aggressive, leading to the metastatic state. Histologic 
changes, from preneoplasia to carcinoma, accompany the promotion and progression 
phases (Christiani, 2000). The changes in DNA like base modification, rearrangement of 
DNA sequence, miscoding of DNA lesion, gene duplication and the activation of 
oncogenes may involve in the initiation of various cancers (Cavenee and White, 1995). 
As with other chronic diseases, cancer too has a multifactorial aetiology, which 
includes both genetic and environmental factors (Gourley et al, 1992). The 
environmental factors are responsible for 80% to 90% of all human cancers. Genetic 
influence, though long been suspected in incidence of cancer, is less conspicuous and 
more difficult to identify (Clemens, 1991). There is probably a complex inter-relationship 
between hereditary susceptibility and environmental carcinogenic stimuli in the causation 
of a number of cancers. 
Among the environmental factors, consumption of tobacco (WHO, 1983), alcohol 
(Kabat et al, 1986; Eskelsen et al, 1993), and dietary factors such as high fat diet, beef 
consumption, food additives and contamination (Ames, 1983) have been related to 
cancer. Many other environmental factors such as sunlight, radiations, pesticides and 
medications (e.g., estrogen) are also known to be related to cancer (Ananthaswamy and 
Pierceall, 1990; Liehr, 1997). Exposures to benzene, arsenic, cadmium, chromium etc. 
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have also been known to cause cancer (Kasai and Nishimura, 1984; Frenkel, 1992; 
Kolachana et al, 1993; Lagorio et ai, 1994). Viruses such as Hepatitis B and C virus are 
causally related to hepatocellular carcinoma (Blumberg et al, 1975). Bacterial infections 
have also been linked to cancer (Parsonnet, 1995). 
Role of ROS in cancer: DNA appears most important in tumor biology (Cotran 
et ai, 1989) since its damage is thought to be involved in all stages of carcinogenesis 
(Halliwell and Gutteridge, 1989; Vile and Morris, 1992; Olinski, 1993). Any agent 
capable of chemically modifying DNA in cell could be carcinogenic. Thus, reactive 
oxygen species, which are known to cause oxidative damage to DNA, are potent 
carcinogens (von Sonntag, 1987a; Halliwell and Aruoma, 1991; Dizdaroglu, 1992; 
Cerutti et ai, 1994; Loft and Poulsen, 1996). Many reports are available explaining the 
role of ROS in a number of human diseases including cancer (Lunec, 1990; Clayson et 
ai, 1994; Ames et ai, 1995; Drexer and Junod, 1996; Pryor, 1997). The role of ROS in 
the development of cancer in humans is further supported by the presence of oxidatively 
damaged DNA products in cancer tissue (Malins and Haimanot, 1991; Olinski et ai, 
1992; Malins et ai, 1993). Reports are available which confirm that ROS have been 
implicated in the mechanisms of cancer such as gastric (Salim, 1992a) and colonic cancer 
(Salim, 1992b). 
When the mutations caused by ROS relate to critical genes such as oncogenes or 
tumor suppressor genes, initiation and/or progression of cancer may result (Loft and 
Poulsen, 1996). With respect to cancer, DNA is considered to be the most important 
target of ROS (Feig et ai, 1994; Ames et ai, 1995). Oxidative damage to DNA includes 
a range of specifically oxidized purines and pyrimidines as well as alkali labile sites and 
strand breaks, formed directly or by repair process (Dizdaroglu, 1994; Breen and 
Murphy, 1995). 
Although, ROS damage all four bases in DNA, mutation are usually related to 
modification of GC base pairs (Retel et ai, 1993). The most abundant of the lesions is 8-
0X0-7, 8-dihydro-2-deoxyguanosine (8-oxo-dG) (Halliwell and Aruoma, 1993; Toyokuni 
et al, 1994), a mutagen resulting in G to T transversions (Kuchino et ai, 1987; Floyd, 
1990; Shibutani et al., 1991) through mispairing with adenine. Besides mispairing, the 
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oxidative products of DNA bases may function in mutagenesis through other mechanisms 
including abnormal interactions with the DNA replicative machinery (Feig and Loeb, 
1993; Weitzman et al., 1994). Oxidative stress has been implicated as an important factor 
in metastasis, notably because it results in a loss of cell adhesion, which is the pre-
requisite for cellular detachment and host tissue invasion (Fidler and Nicolson, 1991; 
Kunduera/., 1995). 
Tobacco carcinogenesis: Tobacco smoking is a worldwide epidemic (Shields, 
2000). Tobacco products are responsible for a significant proportion of human cancers 
(Hecht et al, 1994). Smoking is associated with cancer rates in virtually every organ of 
the body including the lung, oral cavity, esophagus, colon, pancreas, bladder, bone 
marrow, cervix, kidney, larynx, renal pelvis, urinary tract, head and neck, and perhaps 
breast (Hecht et al, 1994; Asami et al, 1996; Shields, 2000; Vainio et al, 2001; Hecht, 
2002; Terry and Rohan, 2002). 
Each cigarette contains a mixture of carcinogens, tumor promoters, and co-
carcinogens (Hoffmann and Hoffmann, 1997; Hoffmann and Hecht, 1990). There are 55 
carcinogens (Table 6A) in cigarette smoke that have been evaluated by the International 
Agency for Research on Cancer (lARC) and for which there is " sufficient evidence for 
carcinogenicity" in either laboratory animals or humans (Hoffmann and Hoffmann, 
1997). Other carcinogens not evaluated by the lARC may also be present. Individual 
pulmonary carcinogens in cigarette smoke, selected from classes of carcinogens in Table 
6A, are, listed in Table 6B. Among the most potent of tobacco carcinogens are tobacco-
specific nitrosamines (TSNs) and polycyclic aromatic hydrocarbons (PAHs) (Shields, 
2000), others being aromatic amines, aldehydes, alkenes and metals (Hecht et al, 1994). 
TSNs are formed during the curing process of tobacco by nitrosation of nicotine and 
related alkyloids (Shields, 2000). Two of the TSNs, 4-(A'-methyl-A'-nitrosamino)-l-(3-
pyridyl)-l-butanone (NNK) and A^'-nitrosonomicotine (NNN) have been widely reported 
to be carcinogenic (Hecht and Hoffmann, 1988; Weitberg and Corvese, 1999; Sheppard 
et al, 2000; Minna, 2003). NNK is believed to be the most abundant carcinogen in 
cigarette smoke (Tithofl et al, 2001). Among the PAHs, benzo[a]pyrene is the 
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compound whose ability to induce lung tumors is well documented. The carcinogens 
listed in Table 6B are also found in ETS (Hecht, 1999). 
There are several determinants of tobacco carcinogen exposure for an active 
smoker. The most important is the number of cigarettes smoked each day and the number 
of years during which the smoker has smoked, both of which are directly related to 
cancer risk. Another determinant is the type of cigarette smoked, as tar and other 
carcinogen constituents are contained in variable amounts (Shields, 2000). These and 
other factors that determine the biologically effective dose of tobacco smoke carcinogens 
are summarized in Table 7. 
Most chemical carcinogens (e.g., PAHs and NNK) are biologically inactive until 
they are transformed into reactive intermediates by cellular enzymes such as cytochrome 
P450s (CYP). These reactive intermediates cause DNA damage in a variety of ways, 
including the formation of carcinogen-DNA adducts, which are carcinogen metabolites 
bound covalently to DNA usually at guanine or adenine (Hecht, 1999; Shields, 2000). 
The alkylation of carcinogens to nucleotides in these adducts, create a promutagenic 
lesion or chromosomal aberration (Shields, 2000). 
Besides metabolic activation pathways, there are competing detoxification 
pathways, and the balance between metabolic activation and detoxification differs among 
individuals and will affect cancer risk (Fig. 3). Thus, if DNA adducts escape cellular 
repair mechanisms and persist, they may lead to miscoding, resulting in a permanent 
mutation. Cells with damaged DNA may be removed by apoptosis, or programmed cell 
death (Hecht, 1999). Executing that decision to undergo apoptosis will protect the 
organism from further carcinogenic events occurring in the damaged cell. In contrast, if 
adducts persist without the execution of apoptosis, mutations in key genes such as p53, 
pl6, or K-ras can accumulate, culminating in tumor formation (West et al, 2003). Thus, 
if a permanent mutation occurs in a critical region of an oncogene or tumor suppressor 
gene, it can lead to activation of oncogene or deactivation of the tumor suppressor gene. 
Multiple events of this type lead to aberrant cells with loss of normal growth control and, 
ultimately, to cancer (Hecht, 1999). 
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Table 6A 
Summary of carcinogens in cigarette smolie 
Carcinogen class* No. of compounds 
Polycyclic aromatic hydrocarbons 10 
Aza-arenes 3 
iV-Nitrosamines 7 
Aromatic amines 3 
Heterocyclic aromatic amines 8 
Aldehydes 2 
Miscellaneous organic compounds 15 
Inorganic compounds 7 
Total 55 
Adapted from Hecht, S.S. (1999) J. Natl. Cancer Inst. 91:1194-1210. 
* Compounds for which there is "sufficient evidence for carcinogenicity" in either 
laboratory animals or humans, according to evaluations by the International Agency for 
Research on Cancer. 
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Table 6B 
Pulmonary carcinogens in cigarette smoke 
Carcinogen class 
Polycyclic aromatic hydrocarbons 
Aza-arenes 
N-Nitrosamines 
Miscellaneous organic compounds 
Inorganic compounds 
Compound** 
Benzo[a]pyrene 
Benzo[b] fl uoran thane 
Benzo[/]fluoranthane 
Benzo[^]fluorantnane 
Dibenzo[a, j]pyrene 
Indeno[ 1,2,^ -cd]pyTene 
Dibenz [a,h] anthracene 
5-Methylchrysene 
Dibenz[a,/i]acridine 
7H-Dibenzo[c,g]carbazole 
A^-Nitrosodiethylamine 
4-(Methylnitrosamino)-1 -(3-pyridyl)-1 -
butanone (NNK) 
1,3-Butadiene 
Ethyl carbamate 
Nickel 
Chromium 
Cadmium 
Polonium-210 
Arsenic 
Hydrazine 
Adapted from Hecht, S.S. (1999) J. Natl. Cancer Inst. 91:1194-1210. 
** Compounds from Table 6A for which there is convincing evidence of pulmonary 
tumorigenicity in at least one species. 
Table 7 
Factors affecting biologically effective dose of tobacco smoke 
carcinogens 
Factor 
Number of cigarettes per day 
Cigarette type 
Smoking topography 
Carcinogen metabolism 
DNA repair 
Cell survival 
Variable 
Filter, filter type (aeration), menthol, 
length, and tar and nicotine content 
Puff inhalation, puff duration, inter-puff 
intervals, and puffs per cigarette 
Metabolic activation and detoxification 
DNA repair enzymes and cell cycle 
Necrosis and apoptosis 
Adapted from Shields, P.O. (2000) Current Oncology Reports 2: 257-262. 
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Nicotine addiction 
X Cigarette smokin 
PAH, NNK and other 
carcinogens 
^ 
g 
Metabolic 
detoxification ^ 
^ Excretion 
Metabolic activation 
f 
DNA adducts 
Persistence Miscoding 
r — , 
Mutations and other changes: 
RAS, MYC, p53, pl6, RB, FHIT 
and other critical genes 
1 r 
Lung cancer 
Repair 
^ TLT 1 
^ Normal 
DNA 
^ ^ Apoptosis 
Fig. 3. Scheme linking nicotine addiction and lung cancer. 
Adapted from Hecht, S.S. (1999) J. Natl. Cancer Inst. 91: 1194-1210. 
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Cancer risk from exposure to tobacco smoke varies widely from person to person, 
depending on the status of particular genes and acquired susceptibilities (Kato et ai, 
1995). Literature shows a relationship between tobacco smoke exposure, carcinogen-
DNA adduct formation, tumor specific mutations (e.g. 53 mutational spectra), and cancer 
risk (Shields, 2000). DNA repair processes are important in determining whether DNA 
adducts persist. There are three mechanisms of DNA repair: direct repair, base excision 
repair, and nucleoside excision repair (Pegg et al., 1995; Sancar, 1996; Singer and Hang, 
1997). As tobacco smoke contains nitrosamines, which can be activated to carcinogens 
by CYP2A6 (Crespi et ai, 1990; Yamazaki et ai, 1992), individuals who carry CYP2A6-
null alleles may also be less efficient at activating tobacco smoke procarcinogens to 
carcinogens. And such carriers may have a decreased risk of developing tobacco-related 
cancers (Law et al, 1997). 
Smoking and lung cancer: Worldwide lung cancer kills over one million people 
each year. Cigarette smoking is the major cause of lung caner. Smoking causes about 
90% of male lung cancer deaths and 75%-80% of female lung cancer deaths in the United 
States each year (Hecht, 1999). As indicated in Fig. 3, the direct interaction of 
metabolically activated carcinogens with critical genes, such as the p53 tumor suppressor 
gene and the Kirsten-ras (Kras) oncogene, establishes the link between nicotine addiction 
and lung cancer (Hecht, 1999). The p53 gene plays a crucial role in the delicate balance 
of cellular proliferation and death. It is mutated in about half of all cancer types, 
including more than 50% of lung cancers. A positive relationship between lifetime 
cigarette consumption and the frequency of p53 mutations and G -> T transversions on 
the non-transcribed DNA strand also has been noted (Greenblatt et ai, 1994; Hussain and 
Harris, 1998). Mutations in codon 12 of the Kras gene are found in 24%-50% of human 
primary adenocarcinomas. These mutations are more common in smokers and ex-
smokers than in non-smokers, which suggests that they may be induced by direct reaction 
with the gene of an activated tobacco smoke carcinogen (Hecht, 1999). Table 8 estimates 
the role of various groups of carcinogen found in cigarette smokers as contributors to 
human lung cancer. The strongest evidence is for PAHs and NNK. 
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Table 8 
Evaluation of roles of specific carcinogens in human lung cancer 
induced by cigarette smoke 
Evaluation of evidence for a role in lung cancer* 
Compounds Presence Pulmonary Human Human Molecular Overall 
in carcinogenicity uptake metabolism changes score 
cigarette in rodents and adduct in human 
smoke formation genes 
Specific PAHs 
Aza-arenes 
NNK, A^ -
nitrosodiethylamine 
Metals 
Miscellaneous 
organic compounds 
Free radicals/ 
oxidative damage 
4 
3 
4 
4 
4 
3 
4 
3 
4 
4 
3 
1 
Adapted from Hecht, S.S. (1999) J. 
* Scores: 1 = inadequate data; 2 : 
Natl. 
4 
1 
4 
1 
1 
3 
3 
1 
3 
1 
1 
3 
Cancer Inst. 91:1194-1210. 
= weak or equivocal evidence; 3 = 
3 
2 
3 
1 
1 
1 
 some 
18 
10 
18 
11 
10 
11 
evidence, 
limited studies; 4 = clear evidence, strong, reproducible studies. 
Note: See Table 6B for details of compound categories. 
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Nicotine and cancer: Nicotine addiction is the reason that people continue to 
smoke. Carcinogens form the link between nicotine addiction and lung cancer (Hecht, 
1999). Although tobacco smoke is an established carcinogen (Shields, 2000) whether 
nicotine is carcinogenic is still debatable. Although some scientists (Hecht, 1999; Sopori, 
2002) do not consider it to be carcinogenic, there are reports according to which it is 
carcinogenic (Hakki et ai, 2001). It has also been considered as pro-angiogenic, cancer 
promoter, and tumor promoter (Wright et ai, 1993; Maneckjee and Minna, 1990; 1994; 
Villablanca, 1998; Hakki et ai, 2001; Minna, 2003). 
The presence of high-affinity, stereospecific nicotine receptors on lung cancer 
cells suggests that nicotine or its metabolites may play a direct role in lung cancer 
pathogenesis (Maneckjee and Minna, 1990; Minna, 1993). Nicotine has been reported to 
contribute to lung carcinogenesis though various mechanisms (Masuda et ai, 2001; Song 
et ai, 2003). Stimulation of nAChRs in non-neuronal cells is one such mechanism. 
nAChRs bind not only nicotine, but also nicotine-derived nitrosamines such as NNN and 
NNK, which are potent lung carcinogens (Minna, 2003). Chronic use of tobacco is also 
associated with pancreatic cancer and pancreatitis. A study suggests that nicotine is a 
major factor in these pathological effects (Rayford, 2001). Another report demonstrates 
that nicotine induces pancreatic injury by a mechanism that involves activation and 
expression of proto-oncogene, H-ras. Development of pancreatic carcinoma in cigarette 
smokers may be the result of activation and mutation of the H-ras gene (Chowdhury et 
ai, 2002). Literature shows that nicotine exposure increases bladder cancer risk, though 
weakly (Zeegers et ai, 2002). Simultaneous exposure to nicotine and hyperoxia has been 
reported to cause tumors in hamsters (Schuller et ai, 1995). 
Nicotine exposure alters the expression of various genes, leading to various 
abnormalities, including tumorigenesis (Arredondo et ai, 2001). By interfering with ACh 
signaling, nicotine can alter the normal balance of cell growth and differentiation, which 
accelerates the squamatization and increases the risk for malignant transformation 
(Arredondo et ai. 2001). Although nicotine has been implicated as a potential factor in 
the pathogenesis of cancer in humans, its mechanism of action in the development of 
cancer remains largely unknown (Sugano et ai, 2001). Increasing evidence supports the 
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notion that nicotine itself may have some carcinogenic potential, acting directly as a 
carcinogen or, more likely, indirectly as a promoter of cancer. Associations of nicotine 
and cancer have been described in terms of both lung and cervical tumor progression in 
humans (Waggoner and Wang, 1994). One of the ways such promotion could occur is by 
inhibiting the process of apoptosis (Hakkier al., 2001). 
Apoptosis or programmed cell death is a process by which the body naturally 
removes the cells that are either not needed or are damaged, a process that is essential to 
normal development and cellular homeostasis (Hakki et al, 2001). Nicotine plays a role 
in modulation of apoptosis, but controversy exists in terms of how it affects this process 
(Hakki et al, 2001). Whereas few studies have demonstrated that nicotine induces 
apoptosis (Berger and Zeller, 1988; Yamamura et al, 1998; Wu et al, 2002), a wide 
range of reports demonstrate that nicotine inhibits apoptosis induced by diverse stimuli 
including tumor necrosis factor, UV light, calcium ionophore, opioids, dexamethasone, 
H2O2, arachidonic acid, etoposide, chemotherapeutic drugs (Wright et al, 1993; 
Maneckjee and Minna, 1994; Sugano and Ito, 2000; Garrido et al, 2001; Hakki et al, 
2001; Sugano et al, 2001; West et al., 2003; Mai et al, 2003). Inhibition of apoptosis by 
nicotine of certain type of human cancer cell lines, including human lung cancer has been 
demonstrated (Waggoner and Wang, 1994; Heusch and Maneckjee, 1998). It has also 
been reported that engagement of nicotine receptors in human lung cancer cells 
suppresses apoptosis (Maneckjee and Minna, 1994). However, the intracellular 
mechnism(s) involved in nicotine suppression of apoptosis is unclear. However, it is 
thought that nicotine stimulates the phosphorylation of the anti-apoptotic B cell 
lymphoma gene 2 (BCL2) to inhibit apoptosis (Mai et al, 2003). Activation of 
serine/threonine kinase Akt by nicotine may also contribute to tobacco-related 
carcinogenesis by regulating two processes critical for tumorigenesis, cell growth and 
apoptosis (West et al, 2003). Thus nicotine-mediated inhibition of apoptosis may 
contribute to the pathogenesis of tobacco-related cancer as well as decrease the efficacy 
of cancer therapies (Wright et al, 1993). 
Nicotine could play an additional role in carcinogenesis through being a pro-
angiogenic agent (Minna, 2003). Angiogenesis is a process necessary for tumor growth 
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and metastasis (Battegay, 1995). Nicotine has been postulated to play an important role in 
tumor angiogenesis, tumor growth, malignancy and metastasis because of increased 
angiogenesis (Wright et al, 1993; Villablanca, 1998; Heeschen et al, 2001; 2002). 
Angiogenic effects of nicotine appear to be mediated through non-neuronal nAChRs 
(Heeschen et al, 2002). Another mechanism of nicotine-induced carcinogenesis is 
enhancement of tissue and DNA damage by nicotine through HOCl-mediated 
chlorination by myeloperoxidase secreted from neutrophils (Masuda et al, 2001). 
Reactive oxygen species produced from cigarette smoke are believed to be 
involved in its carcinogenicity (Asami et al, 1996). Formation of active oxygen species 
by a synergistic effect between polyphenols and nicotine explain the mechanism of 
tobacco carcinogenesis, since the species show genotoxic effects to induce DNA strand 
breaks as well as epigenetic effects to act as cell proliferating signals (Kodama et al, 
1997). Nicotine dependent carcinogenesis has also been demonstrated to proceed by 
growth factor-mediated mechanisms (Rakowicz-Szulczynska et al, 1994). 
Nicotine causes a significant increase in vascular endothelial growth factor 
(VEGF), which is a mitogen, thought to be involved in progression of cancer (Conklin et 
al, 2002). Nicotine exposure results in a decrease in efficacy of anticancer agents such as 
cisplatin and gamma-radiation (Onoda et al, 2001). It also abrogates the growth 
inhibitory effects of all trans-retinoic acid, an anticancer agent, by suppressing its ability 
to induce the tumor suppressors, resulting in the failure of prevention of cancer 
development in smokers (Chen et al, 2002). 
Objectives of the present study 
The review of literature makes it evident that exposure to tobacco smoke damages 
the DNA and is an important carcinogenic factor. But practically, little information is 
available on the effects of nicotine, a major constituent of tobacco smoke, on DNA 
damage. 
In the present study, commercially available calf thymus DNA was purified free 
of proteins and single-stranded regions. The purified DNA was allowed to interact with 
nicotme m solution under UV light of 254 nm. The nicotine-radiant energy modified 
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DNA was characterized by UV and fluorescence spectroscopy, thermal denaturation 
studies, nuclease SI digestibility and hydroxyapatite column chromatography. 
Superoxide anion radical, produced by UV irradiation of nicotine, was detected by 
photosensitized reduction of nitroblue tetrazolium (NBT). Production of the radical was 
confirmed using superoxide dismutase (SOD). 
Antigenicity of nicotine modified DNA was probed by inducing antibodies in 
rabbits. Nicotine modified DNA was found to be highly immunogenic. The specificity of 
antibodies induced by nicotine modified DNA was evaluated by competition ELISA and 
gel retardation assay. The reactivity of circulating antibodies against native and nicotine 
modified DNA in the sera of various smoking-related cancer patients and normal healthy 
persons with different smoking index was determined by inhibition ELISA. 
T,7(penmeniciC 
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MATERIALS 
Calf thymus DNA, nuclease SI, riboflavin, superoxide dismutase, bovine serum 
albumin, agarose, anti-human/anti-rabbit IgG-alkaline phosphatase conjugate, ethidium 
bromide, Coomassie Brilliant Blue G-250 and R-250, sodium dodecyl sulphate, Freund's 
complete and incomplete adjuvants, methylated bovine serum albumin, Tween-20, 
Tween-80, NP-40, Triton X-100, nitroblue tetrazolium, sodium azide, para-
nitrosodimethyl aniline were purchased from Sigma Chemical Company, U.S.A. Protein-
A agarose from Genei, and Ficoll 400 was obtained from Pharmacia Fine Chemicals, 
Sweden. EDTA (disodium salt), chloroform, isoamyl alcohol and glacial acetic acid were 
from Qualigens, India. p-Nitrophenyl phosphate was obtained from Centre for 
Biochemical Technology, New Delhi. Acrylamide, ammonium persulphate, 
bisacrylamide, N, N, N', N'-tetramethylethylene diamine (TEMED), hydroxyapatite were 
from Bio-Rad Laboratory U.S.A. Nicotine was obtained from B.D.H., U.K. All other 
chemicals were of the highest analytical grade available. Polystyrene microtitre flat 
bottom ELISA module strips and plates were purchased from NUNC, Denmark. Dialysis 
tubing was obtained from Sigma Chemical Company, U.S.A. 
Equipments 
Shimadzu UV-240 spectrophotometer equipped with thermo-programmer and 
controller unit, ELISA microplate reader, Elico pH meter model Ll-10 T, ultraviolet 
lamp (Vilber Lourmat, France), agarose gel electrophoresis assembly GNA-100 
(Pharmacia, Sweden); Beckman ultracentrifuge, Avanti 30 table top high speed 
refrigerated centrifuge (Beckman, U.S.A.); polyacrylamide gel electrophoresis assembly 
(Bio-Rad, U.S.A.) and fluorimeter (Hitachi, Japan) were the major equipments used. 
METHODS 
Collection of sera 
Blood samples were collected from healthy individuals with varying smoking 
status (from never-smoker to chain-smoker). Sera were separated from the blood, 
51 
decomplemented at 56°C for 30 min and stored in aliquots at -20°C with 0.1% sodium 
azide. Sera from cancer patients proven with histopathological diagnosis were obtained 
from Department of Radiotherapy, J.N. Medical College Hospital, A.M.U., Aligarh. 
Purification of calf thymus DNA 
Commercially obtained calf thymus DNA was purified free of proteins and single 
stranded regions as described by Ali et al. (1985). DNA (2 mg/ml) was dissolved in 
0.1 X SSC buffer (15 mM sodium citrate and 150 mM sodium chloride, pH 7.3) and then 
mixed with an equal volume of chloroform-isoamyl alcohol (24:1) in a stoppered 
container and gently mixed occasionally for 1 hr. The aqueous layer containing DNA was 
separated from the organic layer and re-extracted with chloroform-isoamyl alcohol. The 
DNA was precipitated with two volumes of cold absolute ethanol and collected on a glass 
rod. After drying in air, the DNA was dissolved in acetate buffer (30 mM sodium acetate 
containing 30 mM zinc chloride, pH 5.0) and treated with nuclease SI (150 units/mg 
DNA) at 37°C for 30 min to remove single stranded regions. The reaction was stopped by 
adding one-tenth volume of 200 mM EDTA, pH 8.0. The nuclease SI treated DNA was 
extracted twice with chloroform-isoamyl alcohol and finally precipitated with two 
volumes of cold ethanol. The precipitate was dissolved in phosphate-buffered saline 
(PBS) (10 mM sodium phosphate containing 150 mM sodium chloride), pH 7.4. 
Determination of DNA concentration 
DNA concentration was estimated colorimetrically by the method of Burton 
(1956) using diphenylamine reagent. 
(a) Crystallization of diphenylamine 
Diphenylamine (2 g) was dissolved in 200 ml boiling hexane. After adding 0.5 g 
of activated charcoal, the hot mixture was filtered through Whatman No. 1 filter paper 
and the filtrate was kept overnight at 4°C and dried at room temperature before use. 
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(b) Preparation of diphenylamine reagent 
750 mg of recrystallized diphenylamine was mixed with 50 ml of glacial acetic 
acid and 0.75 ml of concentrated sulphuric acid. The reagent was prepared fresh before 
use. 
(c) Procedure 
1 ml of DNA sample was mixed with 1.0 ml of IN perchloric acid and incubated 
at 70°C for 15 min. 100 ^1 of 5.43 mM acetaldehyde was added, followed by 2.0 ml of 
freshly prepared diphenylamine reagent. The contents were mixed and incubated at room 
temperature for 16-20 hr. Absorbance was read at 600 nm and the concentration of DNA 
in unknown samples was determined from a standard plot of purified calf thymus DNA. 
Determination of protein concentration 
Protein was estimated by the methods of Lx)wry et al. (1951) and Bradford 
(1976). 
Protein estimation by Folin's-phenol reagent 
The protein estimation by this method utilizes alkali (to keep the pH high), Cu^"*^  
ions (to chelate proteins) and tartarate (to keep the Cu^* ions in solution at high pH). 
(a) Folin-Ciocalteau's reagent 
The reagent was purchased from Centre for Biochemical Technology, New Delhi 
and diluted 1:4 with distilled water before use. 
(b) Alkaline copper reagent 
The components of alkaline copper reagent were prepared as follows: 
(i) Two percent sodium carbonate, 100 mM sodium hydroxide. 
(ii) 0.5 percent copper sulphate in 1 percent sodium potassium tartarate. 
The working reagent was prepared fresh before use by mixing components (i) and 
(ii) in the ratio of 50:1. 
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(c) Procedure 
To 1 ml of protein sample 5 ml of alkaline copper reagent was added and 
incubated for 10 min at room temperature. 1 ml of working Folin-Ciocalteau's reagent 
was added and the tubes were read at 660 nm after 30 min. The concentration of protein 
in unknown sample was determined from a standard plot of bovine serum albumin. 
Protein estimation by dye-binding method 
This assay is based on color change when Coomassie Brilliant Blue G-250 in 
acidic medium, binds strongly to protein hydrophobically and at positively charged 
groups (Bradford, 1976). In the environment of these positively charged groups, 
protonation is suppressed and a blue color is observed (Xirax-595 nm). 
(a) Dye preparation 
100 mg Coomassie Brilliant Blue G-250 was dissolved in 50 ml of 95% ethanol 
and 100 ml of 85% (v/v) orthophosphoric acid was added. The resulting solution was 
diluted to a final volume of 1 litre and filtered through Whatman No. 1 filter paper to 
remove undissolved particles. 
(b) Protein assay 
To 1 ml of solution containing 10-100 [xg protein, 5 ml of dye solution was added 
and the contents were mixed by vortexing. The absorbance was read at 595 nm after 5 
min against a reagent blank. 
Modification of calf thymus DNA by nicotine 
Aqueous solutions of purified native calf thymus DNA (50 ng/ml) and nicotine 
(150 ng/ml) both in phosphate buffered saline (PBS), pH 7.4, were irradiated under 254 
nm UV light for 60 min at room temperature. After irradiation, excess of nicotine was 
removed by extensive dialysis against PBS. 
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Spectroscopic analysis 
(a) Ultraviolet spectroscopy 
The ultraviolet spectra of modified and unmodified calf thymus DNA were recorded 
in the wavelength range of 200 - 400 nm on a Shimadzu UV-240 spectrophotometer. 
Spectroscopic studies were also done on unirradiated, 30 min and 60 min irradiated 
nicotine before and after dialysis; unirradiated, 30 min and 60 min irradiated native 
DNA before and after dialysis; unirradiated and 30 min irradiated DNA-nicotine 
mixture before and after dialysis. 
UV spectra of DNA samples modified with a range of nicotine concentrations 
were also taken. DNA samples were mixed with nicotine and irradiated under UV 
light for 60 min. Keeping the DNA concentration constant; nicotine concentration 
was increased from three to 12 times to that of DNA. 
To study the effect of incubation time on nicotine- modified DNA, unirradiated 
aqueous solution of DNA (50 Hg/ml) modified with nicotine (150 [i^m\) was 
incubated at 37°C for 74 hr. UV spectra were taken at an interval of 24 hr. Individual 
solutions of DNA (50 M.g/ml) and nicotine (150 ng/ml) incubated separately under 
similar conditions served as control. 
The effect of pH on DNA-nicotine interaction was also studied. DNA was 
mixed with nicotine and UV irradiated for 60 min. Excess of nicotine was removed 
by dialysis as mentioned earlier. Different samples of DNA modified with nicotine 
were dialysed under different pH ranging from 7.4 to 10.0. UV spectra of all the 
samples were recorded after dialysis. 
(b) Fluorescence spectroscopy 
Fluorescence emission spectroscopy of native and modified DNA samples using 
ethidium bromide was performed on a fluorimeter. 
%^ -if 
Absorption - temperature scan ^ ^ ., ,, ^ 
Thermal denaturation analysis of nucleic acids was performed in order to 
ascertain the degree of modification incurred on the nucleic acids by determining mid 
point melting temperature (Tm). Native and modified samples were subjected to heat 
denaturation on a Shimadzu UV-240 spectrophotometer coupled with a temperature 
programmer and controller assembly (Hasan and AH, 1990). All the samples were melted 
from 30°C to 95°C at a rate of 1.5°C / min after 10 min equilibration at SOX. The change 
in absorbance at 260 nm was recorded with increasing temperature. Percent denaturation 
was calculated as follows: 
A - A 
Percent denaturation = — ^^- x 100 
where, AT = Absorbance at a temperature T°C. 
Amax = Final maximum absorbance on the completion of 
denaturation (95°C). 
A30 = Initial absorbance at 30°C. 
Hydroxyapatite column chromatography 
Hydroxyapatite column chromatography was employed to discriminate nucleic 
acids endowed with different secondary structures. Native and nicotine-modified DNA 
(in 10 mM Na-phosphate buffer, pH 6.8) were chromatographed on hydroxyapatite 
column as described by Dardalhon and Averback (1988). Batch elution was carried out 
with 125 mM and 250 mM Na-K-phosphate buffer, pH 6.8 at a flow rate of 15 ml/hr. 
Fractions of 3 ml were collected and absorbance monitored at 260 nm. 
Nuclease SI digestibihty 
Native and modified DNA samples were characterized by nuclease SI 
digestibility (Matsuo and Ross, 1987). One microgram each of native and modified DNA 
in acetate buffer (30 mM each of sodium acetate and zinc chloride, pH 5.0) were treated 
with nuclease SI (20 units/^g DNA) for 30 mm at 37°C. The reaction was stopped by 
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adding one-tenth volume of 200 mM EDTA, pH 8.0. The digested and control samples 
were subjected to agarose gel electrophoresis. 
(a) Gel preparation 
Agarose (1%) in TAE buffer (40 mM Tris-acetate, pH 8.0 containing 2 mM 
EDTA) was dissolved by heating. The solution was cooled to about 50°C and then 
poured onto gel tray and allowed to solidify at room temperature. 
(b) Sample preparation and loading 
Native and modified DNA samples treated with nuclease SI were mixed with 
one-tenth volume of sample buffer (0.125% bromophenol blue, 30% Ficoll 400, 500 mM 
EDTA in lOX electrophoresis buffer). The samples were loaded in the wells and 
electrophoresed for 2 hr at 30 mA. The gels were stained with ethidium bromide (0.5 
^ig/ml), viewed by illumination under UV light and photographed. 
Detection of superoxide radicals 
Superoxide anion radical was detected by photosensitized reduction of nitroblue 
tetrazolium (NBT), leading to the formation of a blue coloured product, nitroblue 
formazan (Nakayama et ai, 1983). 
The protocol for detection of the radical was standardized by studying the 
generation of the radical by riboflavin under fluorescent light, ultraviolet light (254 and 
365 nm) and in dark. A total volume of 3.0 ml contained 50 mM sodium phosphate 
buffer, pH 8.0, 0.1 mM EDTA, 0.06% detergent (Triton X-100/NP-40/Tween-20A^ween-
80), 15 ^M riboflavin and 0.033 |iM NBT. Immediately after mixing, the reaction was 
carried out in the presence of fluorescent / UV-light. Absorbance at 560 nm was recorded 
at an interval of 10 min. 
To detect the radical produced on UV irradiation of nicotine, instead of riboflavin, 
varying concentrations of nicotine (450 fxg/ 900 [ig/ 1350 [ig) were added in the reaction 
mixture. Generation of the radical by nicotine in the presence of DNA was also studied. 
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Production of superoxide radical by riboflavin and nicotine was confirmed by 
monitoring the inhibition of formation of a blue coloured product in the presence of 
superoxide dismutase (SOD). 
Immunization protocol 
(a) Immunogen preparation 
Three immunogens were prepared: 
(i) Aqueous solutions of calf thymus DNA (100 [ig/mY) and nicotine (300 
pig/ml) both in PBS were mixed and irradiated under 254 nm UV light for 60 
min. Excess of nicotine was removed by extensive dialysis against PBS. The 
immunogen is abbreviated as Nic*DNA (-Nic). 
(ii) Aqueous solutions of calf thymus DNA (100 [ig/ml) and nicotine (300 
Hg/ml) were mixed and irradiated in the same manner but excess of nicotine 
was not removed and immunization was done in presence of excess of 
nicotine. The immunogen is abbreviated as Nic*DNA (+Nic). 
(iii) Aqueous solution of nicotine (300 pig/ml) was prepared for direct 
immunization. 
(b) Immunization 
Modified DNA (50 ng) or nicotine (150 |j,g) were mixed with an equal volume 
(w/w) of methylated BSA and emulsified with an equal volume of complete Freund's 
adjuvant and injected intramusculariy in female rabbits. Subsequent injections were given 
in incomplete Freund's adjuvant. Each animal received a total of 6 injections over a 
period of 6 weeks. 
(c) Bleeding 
Blood was collected from marginal vein of the ear; serum was separated and 
decomplemented by heating at 56°C for 30 minutes. Pre-immune sera were collected 
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prior to immunization. The sera were stored in small aliquots at -20°C with 0.1% sodium 
azide as preservative. 
Isolation of IgG by Protein-A agarose 
Serum IgG was isolated by affinity chromatography on Protein-A agarose 
column. Serum (0.3 ml) diluted with equal volume of PBS, pH 7.4 was applied to column 
(12 X 45 mm) equilibrated with the same buffer. The wash through was recycled 2-3 
times. Unbound IgG was removed by extensive washing with PBS, pH 7.4. The bound 
IgG was eluted with 0.58% acetic acid in 0.85% sodium chloride (Goding, 1976) and 
neutralized immediately with 1 ml of 1.0 M Tris-HCl, pH 8.5. Three ml fractions were 
collected and read at 251 and 278 nm. The IgG concentration was determined considering 
1.4 OD280 = 1.0 mg IgG/ml. The isolated IgG was dialyzed against PBS, pH 7.4 and 
stored at -20°C with 0.1% sodium azide. 
Polyacrylamide gel electrophoresis for proteins 
Polyacrylamide slab gel electrophoresis was performed under denaturing 
conditions as described by Laemmli (1970). The following stock solutions were prepared; 
(a) Acrylamide-bisacrylamide (30:0.8) 
A stock solution was prepared by dissolving 30 gm of acrylamide and 0.8 gm 
bisacrylamide in distilled water to a final volume of 100 ml. 
(b) Resolving gel buffer 
A stock solution was prepared by dissolving 36.3 gm Tris base in 48.0 ml of IN 
HCl. The contents were mixed, pH adjusted to 8.8 and the final volume brought to 100 
ml with distilled water. 
(c) Stacking gel buffer 
6.05 gm Tris was dissolved in 40 ml distilled water; pH titrated to 6.8 with IN 
HCl and the final volume adjusted to 100 ml with distilled water. 
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(d) Electrode buffer 
3.03 gm Tris, 14.4 gm glycine and 1.0 gm SDS were dissolved in distilled water, 
pH adjusted to 8.3 and final volume made up to one litre. 
(e) Procedure 
Glass plates, separated by 1.5 mm thick spacer were sealed with 1% agarose. The 
resolving gel mixture was prepared by mixing the components in the appropriate volume 
and poured into the space between the glass plates leaving sufficient space at the top for 
the stacking gel. After the polymerization of separating gel, stacking gel mixture was 
poured and allowed to solidify. Protein samples containing 10% glycerol and 0.002% 
bromophenol blue were applied and electrophoresis was carried out at 60V for 6-8 hrs. 
Staining of the gel was achieved with 0.1% Coomassie Brilliant Blue R-250 (in 25% iso-
propanol and 10% glacial acetic acid). Destaining was carried out in mixture of 10% 
acetic acid and 10% methanol. 
Recipe for 7.5% SDS-PAGE 
Solutions 
Acrylamide-bisacrylamide 
Stacking gel buffer 
Resolving gel buffer 
Distilled water 
10% SDS 
1.5% ammonium persulphate 
TEMED 
Stacking gel 
1.25 ml 
2.5 ml 
-
5.65 ml 
0.1ml 
0.5 ml 
0.75 lal 
Resolving gel 
7.5 ml 
-
3.75 ml 
16.95 ml 
0.3 ml 
1.5 ml 
15.0^1 
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Immunological detection of antibodies 
Sera were tested for antibodies by enzyme linked immunosorbent assay and gel 
retardation (band shift) assay. To determine the antigenic specificity of the antibodies, 
competition ELISA was performed. 
(a) Enzyme linked immunosorbent assay 
The following reagents were prepared in distilled water and used in enzyme 
immunoassay. 
(i) Buffers and reagents 
Tris buffered saline (TBS) 
10 mM Tris, 150 mM NaCl, pH 7.4 
Tris buffered saline-Tween- 20 (TBS-T) 
20 mM Tris, 144 mM NaCl, 2.68 mM KCl 
pH 7.4, containing 500 ^1 Tween- 20/L. 
Carbonate-bicarbonate buffer 
15 mM sodium carbonate, 35 mM sodium bicarbonate, pH 9.6, containing 2 mM 
magnesium chloride. 
Substrate 
500 ng p-nitrophenyl phosphate (p-NPP)/ml carbonate-bicarbonate buffer, pH 
9.6. 
(ii) Procedure 
Antibodies were detected by ELISA using polystyrene microtitre plates as solid 
support (Aotsuka et al, 1979). One hundred microlitre of 2.5 ^g/ml antigen in TBS, pH 
7.4 was coated in test wells of microtitre plates. The plates were incubated for 2 hr at 
37°C and overnight at 4°C. The antigen-coated wells were washed three times with TBS-
T to remove unbound antigen. Unoccupied sites were blocked with 150 \x\ of 1.5% BSA 
in TBS for 4 - 5 hrs at room temperature. The plates were washed once with TBS-T and 
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antibody (100 ^I/well) to be tested, were diluted in TBS and added to each well. After 2 
hr incubation at 37°C and overnight at 4°C, the plates were washed four times with TBS-
T and an appropriate anti-immunoglobulin alkaline phosphatase conjugate was added to 
each well. After incubation at 37°C for 2 hr, the plates were washed four times with TBS-
T and three times with distilled water and developed using p-nitrophenyl phosphate 
substrate. The absorbance was recorded at 410 nm on an automatic microplate reader. 
Each sample was run in duplicate. The control wells were treated similarly but were 
devoid of antigen. Results were expressed as a mean of 
Atest "Acontrol-
(b) Competition ELISA 
The antigenic specificity of the antibodies was determined by competition ELISA 
(Hasan et ai, 1991). Varying amount of inhibitors (0-20 |ig/ml) were mixed with a 
constant amount of antiserum or IgG. The mixture was incubated at room temperature for 
2 hr and overnight at 4°C. The immune complex thus formed was coated in the wells 
instead of the serum. The remaining steps were the same as in direct binding ELISA. 
Percent inhibition was calculated using the formula 
Percent inhibition = 1 '""'''^ x 100 
A 
'^uninhibited 
(c) Band shift assay 
For the visual detection of antigen-antibody binding and immune complex 
formation, gel retardation assay was performed (Sanford et ai, 1988). A constant amount 
of antigen (native and modified DNA) was incubated with varying amounts of IgG in 
PBS, pH 7,4 for 2 hr at 37°C and overnight at 4°C. One-tenth volume of 'stop mix' dye 
was added to the mixture and electrophoresed on 1% agarose for 2 hr at 30 mA in TAB 
(40 mM Tris, 5 mM sodium acetate, 1 mM EDTA) buffer, pH 7.9. The gels were stained 
with ethidmm bromide (0.5 ^g/ml), visualized under UV light and photographed. 
^suCts 
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Physicochemical characteristics of nicotine 
In the present study, hydrogen tartarate salt of nicotine was used, as it was easily 
soluble in aqueous medium. The solution was prepared in PBS, pH 7.4 and subjected to 
UV absorption studies. The UV spectrum showed A,max at 260 nm, a major shoulder at 
255 nm and a minor shoulder at 263 nm, on each side of the Xmax. UV absorption profile 
of nicotine on UV irradiation (254 nm) showed substantial changes such as a blue shift at 
A,max and Xmin and hyperchromicity at both the wavelengths. Both shift and 
hyperchromicity were found to increase with increasing irradiation dose. On UV 
irradiation of nicotine, a peak has emerged at 360 nm and its absorbance increased with 
increasing dose of irradiation. An increase in absorbance at 280 nm and a gradual 
disappearance of both the shoulders was also observed as a result of UV irradiation (Fig. 
4, Table 9). 
It is known that a DNA sample of 50 ^g/ml concentration gives 1.0 absorbance at 
-260 nm. In the case of nicotine A260 =1.0 was obtained at a concentration of 150 ng/ml. 
In other words, when DNA and nicotine were taken in the same concentration (|ig/ml) 
A260 for DNA was thrice to that of nicotine. To have similar A260 for DNA and nicotine, 
their concentration was taken in the ratio of 1:3 throughout these investigations. 
Standardization of the protocol of DNA modification by nicotine 
To standardize the protocol of DNA modification by nicotine following factors 
were taken into account: UV irradiation dose (at 254 nm), dialysis, nicotine 
concentration, incubation time, and pH. 
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Fig. 4. Ultraviolet absorption spectra of unirradiated (—), 30 min irradiated ( ), and 
60 min irradiated (-•-•-) nicotine 
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Table 9 
Comparison of UV absorption characteristics of nicotine before and 
after UV irradiation 
Parameters Unirradiated 30 min irradiated 60 min irradiated 
nicotine nicotine nicotine 
Xmax (nm) 260 
Percent shift in Xmax 
Absorbance at Xmax 0.954 
Percent hyperchromicity at X,max 
"Krmn (nm) 225 
Percent shift in Xmin 
Absorbance at Xmin 0.225 
Percent hyperchromicity at Xmin 
Major shoulder at (nm) 255 
Minor shoulder at (nm) 
Minor peak at (nm) 
Absorbance at 360 nm 
Absorbance at 280 nm 
263 
256 
1.5 
1.074 
12.6 
222.5 
1.11 
0.675 
200 
255 
263 
240 
7.7 
1.392 
45.9 
220 
2.22 
1.026 
356 
No major 
shoulder 
No minor 
shoulder 
No minor 
peak 
0.0 
0.0 
360 
0.222 
0.18 
360 
0.369 
0.39 
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(i) UV irradiation dose 
The DNA-nicotine mixture was UV irradiated for 30 and 60 min. After irradiation 
the mixture showed remarkable changes in its UV absorption pattern. Blue shift at Xmax 
and Xmin, hyperchromicity at both the wavelengths, emergence of a small peak at 360 
nm and gradual disappearance of shoulder at 255 nm were the changes observed. 
Absorbance at 280 nm was also increased. All these changes were directly proportional to 
irradiation dose (Fig. 5 and Table 10). Native DNA on UV irradiation for 60 minutes 
showed almost no change in UV absorption spectra. Effects of UV irradiation were 
persistent after dialysis, which was performed to remove nicotine. Blue shift in Xmax and 
Xmin persisted after dialysis, but instead of hyperchromicity, now hypochromicity was 
observed at both wavelengths (Fig. 6 and Table 11). In subsequent studies 60 min UV 
irradiation of DNA-nicotine was employed. 
(ii) Dialysis 
DNA-nicotine mixture samples (unirradiated, 30 min irradiated and 60 min 
irradiated) were dialysed to remove nicotine. Dialysis of DNA-nicotine complex resulted 
in remarkable changes in the UV spectral profile of all the three samples as is evident 
from Fig. 5, 6 and Table 12. Maxima and minima of all the three samples were changed 
after their dialysis. Dialysis also resulted in alteration in absorbance values at A.max, 
Xmin, 260 nm and 280 nm. Minor peak (360 nm) and shoulder (255 nm) also disappeared 
after dialysis. 
(iii) Nicotine concentration 
Keeping all other factors (DNA concentration, irradiation dose etc) constant, 
nicotine concentration was increased in the DNA-nicotine mixture from three to that of 
DNA concentration to 12 times. Increased absorbance over the entire UV range was 
observed with increasing nicotine concentration (Fig. 7). Nicotine concentration equal to 
three times to that of DNA was chosen for DNA modification throughout the present 
study. 
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Fig. 5. Ultraviolet spectra of unirradiated (—), 30 min irradiated ( ), and 60 min 
inadiated (-•—) DNA- nicotine complex before dialysis. 
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Table 10 
Comparison of UV absorption characteristics of DNA-nicotine complex 
before and after UV irradiation, without dialysis 
Parameters 
^max (nm) 
Percent shift in Xmax 
Absorbance at Xmax 
Percent hyperchromicity at 
Xmin (nm) 
Percent shift in Xmin 
Absorbance at Xmin 
Percent hyperchromicity at 
Shoulder at (nm) 
Minor peak at (nm) 
Absorbance at 360 nm 
Absorbance at 260 nm 
Absorbance at 280 nm 
Xmax 
A,min 
DNA + nicotine 
NoUV 
irradiation 
258 
-
1.9 
-
227 
-
0.65 
-
255 
No minor 
peak 
-
1.88 
0.45 
30 min UV 
irradiation 
258 
0 
1.94 
2.1 
225 
0.88 
0.97 
49.2 
255 
360 
0.12 
1.92 
0.53 
60 min UV 
irradiation 
252 
2.3 
2.1 
10.5 
222 
2.2 
1.48 
127.7 
No shoulder 
360 
0.3 
2.0 
0.74 
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Fig. 6. Ultraviolet spectra of uninadiated (. ..), 30 min irradiated (- - •), '^^^ 60 min 
iiTadiatcd (—) DNA-nicotme complex after dialysis. 
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Table 11 
Comparison of UV absorption characteristics of DNA-nicotine complex 
before and after UV irradiation, after dialysis 
Parameters 
Xmax (nm) 
Percent shift in A,max 
Absorbance at A.max 
Percent hypochromicity at Xmax 
^min (nm) 
Percent shift in A,min 
Absorbance at Amin 
Percent hypochromicity at Xmin 
Absorbance at 260 nm 
Absorbance at 280 nm 
Absorbance ratio (A260/A280) 
DNA + nicotine 
NoUV 
irradiation 
260 
-
1.3 
-
237 
-
0.93 
-
1.32 
0.84 
1.57 
30min UV 
irradiation 
260 
0 
1.2 
7.7 
236 
0.42 
0.76 
18.3 
1.2 
0.73 
1.64 
60 min UV 
irradiation 
258 
0.77 
1.1 
15.4 
235 
0.84 
0.65 
30.1 
1.02 
0.61 
1.67 
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Table 12 
Comparison of UV absorption characteristics of unirradiated, 30 min 
irradiated and 60 min irradiated DNA-nicotine complex before and 
after dialysis 
Parameters 
Xmax (nm) 
Absorbance at ^max 
Xmin (nm) 
Absorbance at A,min 
Shoulder at (nm) 
Minor peak at (nm) 
Absorbance at 260 nm 
Absorbance at 280 nm 
Unirradiated DNA-
nicotine complex 
Before 
dialysis 
258 
1.9 
227 
0.65 
255 
No minor 
.peak 
1.88 
0.45 
After 
dialysis 
260 
1.3 
237 
0.93 
No 
shoulder 
No minor 
peak 
1.32 
0.84 
30 min irradiated 
DNA-nicotine 
complex 
Before 
dialysis 
258 
1.94 
225 
0.97 
255 
360 
1.92 
0.53 
After 
dialysis 
260 
1.2 
236 
0.76 
No 
shoulder 
No 
minor 
peak 
1.2 
0.73 
60 min irradiated 
DNA-nicotine 
complex 
Before 
dialysis 
252 
2.1 
222 
1.48 
No 
shoulder 
360 
2.0 
0.74 
After 
dialysis 
258 
1.1 
235 
0.65 
No 
shoulder 
No 
minor 
peak 
1.02 
0.61 
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Fig. 7. Ultraviolet spectra of DNA modified with varying concentrations of nicotine, 
irradiated for 60 min The nicotine concentration was three times (-•- 2), six 
times (- - 3), nine times (—4), and twelve times (- - 5) to that of DNA 
concentration Native DNA (—1) served as control No dialysis was performed 
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(iv) Incubation time 
Incubation of DNA-nicotine mixture without UV irradiation for a period of up to 
72 hours showed no change in UV spectra (Fig. 8). During these studies UV irradiation 
of DNA-nicotine mixture was performed without incubation. 
(v)pH 
In order to check whether or not nicotine is bound to polyanionic DNA, the 
irradiated DNA-nicotine mixture was divided into four aliquots. Each aliquot was 
dialysed at different pH ranging from 7.4 to 10. UV spectra of all 4 samples showed no 
significant change (Fig. 9), thus, ruling out the possibility of electrostatic interaction 
between DNA and nicotine. DNA modification by nicotine was carried out at 
physiological pH throughout these investigations. 
Final Protocol for DNA modification by nicotine 
Stock DNA and stock nicotine were prepared in PBS, pH 7.4. The two were 
diluted and mixed such that nicotine concentration (in |a.g/ml) was thrice to that of DNA. 
The mixture was immediately UV irradiated for 60 min. Extensive dialysis using PBS 
was done to remove nicotine. DNA modified in such fashion is referred as Nic*DNA (-
Nic). Minus sign prefixing the nicotine in parentheses indicates that excess nicotine 
has been removed by dialysis. This antigen was used in all experiments, including 
immunization, throughout the study. In some studies including immunization Nic*DNA 
(+Nic) was also used. Plus sign indicates that the mixture was used without dialysis. 
Figure 10 shows spectra of the Nic*DNA (-Nic) and nDNA. On modification by 
nicotine, DNA showed around 14% hypochromicity and a shift in minima from 230 nm 
to 235 nm. 
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Fig. 8. Ultraviolet absorption spectra depicting the effect of incubation time on DNA-
nicotine mixture. Aqueous solution of nicotine (150 |J.g/ml) and DNA (50 
J^Lg/ml) were mixed and mcubated at 37°C for 0 hr (—), 24 hr ( ), 48 hr (....) 
and 72 hr (-•-•-). Irradiation and dialysis were not performed. 
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Fig. 9. Ultraviolet absorption spectra of DNA-nicotine irradiated complex dialysed at 
different pH. Aqueous solution of nicotine (150 p-g/ml) and DNA (50 ^ig/ml) 
were mixed, irradiated for 60 min, and dialysed with buffers of pH 7.4 (....), 8.0 
(- - -), 9.0 (—) and 10.0 (—.-). 
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Fig. 10. Ultraviolet absorption spectra of native DNA (—) and Nic*DNA (-Nic) (- - -). 
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Fluorescence spectroscopy of native and modified DNA 
Fluorescence spectra of native DNA and Nic* DNA (-Nic) were taken in presence 
of ethidium bromide (Fig. 11). Fluorescence intensity of Nic*DNA (-Nic) was lesser than 
that of nDNA at all the wavelengths (from 350 to 500 nm). The decrease in the intensity 
indicates lesser intercalation of ethidium bromide in the modified DNA than nDNA, 
which may be due to the change in DNA secondary structure. 
Thermal melting of native and modified DNA 
Thermally induced transitions were measured spectrophotometrically at 260 nm 
by heating nucleic acid samples at a rate of 1.5°C per min. Melting curves were recorded 
at temperatures from 30°C to 95°C. Increase in UV absorption at 260 nm was taken as a 
measure of denaturation. Figure 12 shows the thermal denaturation profile of native and 
modified DNA. Tm was found to be 88°C in case of nDNA and 80°C in Nic*DNA (-
Nic). A net decrease of 8°C in Tm may be due to structural alteration of DNA. The 
thermal denaturation properties of native and modified DNA are summarized in Table 13. 
Hydroxyapatite column chromatography 
Nucleic acids with different secondary structures have more affinity for 
hydroxyapatite than flexible, disordered polymers. Fractionation of nucleic acid samples 
was carried out on the basis of this property of hydroxyapatite. 
DNA samples (modified and unmodified) in 10 mM Na-K-phosphate buffer, pH 
6.8, were applied to hydroxyapatite column, equilibrated with the same buffer. After 
washing the unbound material, stepwise elution was carried out using 125 mM and 250 
mM Na-K-phosphate buffer, pH 6.8. The chromatogram obtained with native DNA 
showed only one peak, centred at 250 mM buffer (Fig. 13a). The elution profile of 
Nic*DNA (-Nic) showed a minor peak eluting with 125 mM buffer and a major peak 
eluting with 250 mM buffer (Fig. 13b). The minor fraction peak may be attributed to the 
generation of smgle strand breaks. 
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Fig. 11. Fluorescence emission spectra of native DNA (—) and Nic*DNA (-Nic) (-
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Fig. 12. Thermal melting profile of native DNA (•) and Nic*DNA (-Nic) (A). 
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Table 13 
Ultraviolet and thermal denaturation characteristics of native DNA and 
Nic*DNA (-Nic) 
Parameters 
Absorbance ratio (A260/A280) 
Percent hyperchromicity at 95°C 
Melting temperature (Tm), °C 
Onset of duplex melting, °C 
Nativ( 
1.85 
33.6 
88.0 
75.0 
5 DNA Nic*DNA (-Nic) 
1.6 
21.9 
80.0 
55.0 
0.7 
^ 0 . 6 
B 
S 0.5 
H 
< 0.4 
U 
U 
5 0-3 
OS 
O 0.2 
n 
^ 0.1 
0.0 
0.17SM 
^ ^ 
O.^.^OM 
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Fig. 13, Hydroxyapatite column chromatography of (a) native DNA and (b) Nic*DNA (-
Nic). 
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Nuclease SI digestibility 
Native DNA and Nic*DNA (-Nic) were digested with nuclease SI (20 units/^g 
DNA) for 30 minutes. The controls were native DNA and Nic*DNA (-Nic) without SI 
treatment. All the four samples were electrophoresed on 1% agarose gel. Nuclease SI 
treated nDNA showed electrophoretic migration pattern and fluorescence intensity almost 
identical to that of non-Sl treated nDNA. On the other hand, nuclease SI treated 
Nic*DNA (-Nic) showed enhanced electrophoretic mobility when compared to non-Sl 
treated Nic*DNA (-Nic) (Fig. 14). 
Detection of superoxide anion radicals 
It is well known that riboflavin on illumination generates superoxide anion 
radical. The generation was monitored by reduction of nitroblue tetrazolium (NBT). In 
order to optimise the superoxide generation, illumination time and dose dependent 
response of riboflavin was studied. It is evident from the curves (Fig. 15) that 20 min 
illumination of fluorescent or UV light caused optimum generation of the radical. 
However, negligible generation was detected when samples were kept in dark (Fig. 15). 
Dose dependent experiment carried out with varying amount of riboflavin showed 
optimum production of the radical at 15 \iM concentration (Fig. 16). 
To standardize the protocol of superoxide radical detection, three sets of 
illumination light (fluorescent, UV 254 nm and UV 365 nm) and four sets of detergents 
(Triton X-100, NP-40, Tween-20 and Tween-80) were used. Under fluorescent light all 
four detergents (along with EDTA) did not show superoxide generation in the absence of 
riboflavin (Fig. 17-20). However, under UV light (254 nm and 365 nm) Triton X-100 and 
NP-40 showed sufficient generation of the radical even in the absence of riboflavin while 
Tween-20 and Tween-80 showed negligible generation under similar conditions (Fig. 21-
28). This observation suggests Tween-20 and Tween-80 as better choices over Triton X-
100, which was till now the most-commonly used detergent in superoxide radical 
generation protocols. 
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Fig. 14. Nuclease SI digestibility of native DNA and Nic*DNA (-Nic). Lane 1 contained 
nDNA^while lane 2 contained nDNA treated with nuclease SI; lane 3 contained 
Nic*DNA (-Nic), while lane 4 contained Nic*DNA (-Nic) treated with nuclease 
SI. Electrophoresis was carried out on 1% agarose gel for 2 hr at 30 mA. 
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Fig. 15. Time dependent generation of superoxide anion radical by riboflavin in 
fluorescent light, UV light, and in dark. 
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Fig. 16. Superoxide anion radical generation under varying concentrations of riboflavin. 
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Fig. 17. Time dependent generation of superoxide anion radical under fluorescent light 
using sodium phosphate buffer + NBT as control and Tnton X-100 as detergent 
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Fig. 18. Time dependent generation of superoxide anion radical under fluorescent light 
using sodium phosphate buffer + NBT as control and NP-40 as detergent. 
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Fig. 19. Time dependent generation of superoxide anion radical under fluorescent light 
using sodium phosphate buffer + NBT as control and Tween-20 as detergent. 
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Fig. 20. Time dependent generation of superoxide anion radical under fluorescent light 
using sodium phosphate buffer + NBT as control and Tween-80 as detergent. 
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Fig. 21. Time dependent generation of superoxide anion radical under UV light (254 nm) 
using sodium phosphate buffer + NBT as control and Tnton X-100 as detergent. 
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Fig. 22. Time dependent generation of superoxide anion radical under UV light (254 nm) 
using sodium phosphate buffer + NBT as control and NP-40 as detergent. 
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Fig. 23. Time dependent generation of superoxide anion radical under UV light (254 nm) 
using sodium phosphate buffer + NBT as control and Tween-20 as detergent 
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Fig. 24. Time dependent generation of superoxide anion radical under UV light (254 nm) 
using sodium phosphate buffer + NBT as control and Tween-80 as detergent. 
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Fig. 25. Time dependent generation of superoxide anion radical under UV light (365 nm) 
using sodium phosphate buffer + NBT as control and Triton X-100 as detergent. 
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Fig. 26. Time dependent generation of superoxide anion radical under UV light (365 nm) 
using sodium phosphate buffer + NBT as control and NP-40 as detergent. 
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Fig. 27. Time dependent generation of superoxide anion radical under UV light (365 nm) 
using sodium phosphate buffer + NBT as control and Tween-20 as detergent. 
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Fig. 28. Time dependent generation of superoxide anion radical under UV light (365 nm) 
using sodium phosphate buffer + NBT as control and Tween-80 as detergent. 
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Pattern of generation of the radical by riboflavin in presence of EDTA and Triton 
X-100 as a detergent was similar under all the three lights (fluorescent, UV 254 and UV 
365) (Fig. 17, 21 and 25). Similar results were obtained in case of NP-40, Tween-20 and 
Tween-80 (Fig 18-28). 
The essentiality of a detergent in the reaction mixture for the generation of 
radical is evident. The curves (Fig. 17-28) started to decline after few minutes, which 
show that the radicals generated by riboflavin in the absence of a detergent were short 
lived. The essential requirement of EDTA is also evident from the results. Without 
EDTA riboflavin could generate superoxide but time required for sufficient generation of 
the radical was high and in most cases yield was found to be low. In the absence of 
detergent and EDTA only negligible amount of the radical could be generated, whereas 
presence of both detergent and EDTA resulted in high yield of the radical and that too in 
a shorter period of time. 
Similar to the standardization of the protocol for detection of superoxide radical 
generated by riboflavin, the protocol for detection of superoxide radical generated by 
nicotine was also standardized (Table 14). When EDTA or detergent or both were 
missing from the system, very little radical could be detected, as is evident from low A560 
values. Thus, in order to appropriately detect the radical generated after UV irradiation of 
nicotine, presence of both EDTA and a detergent was found essential. 
Unlike, riboflavin, nicotine could not generate the radical under fluorescent light. 
With all the essential ingredients present and varying nicotine concentration (75 |ig, 150 
lag and 300 |j.g per ml) no significant production of radical was observed suggesting that 
UV irradiation appears to be essential for the generation of the radical. 
For the detection of superoxide anion radical generated by nicotine under 254 nm 
UV light, two detergents (Tween-20 and Tween-80) were used. It is evident from Fig. 29 
and 30 that nicotine generated superoxide radical when exposed to UV light and the 
generation was directly proportional to nicotine concentration. However, DNA alone did 
not generate the radical (Figs.31, 32). 
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Table 14 
Standardization of the protocol for the detection of superoxide radical, 
generated by nicotine on exposure to UV Hght 
Sodium Detergent EDTA NBT Nicotine As^ o after 30 A560 after 60 
phosphate min min 
buffer irradiation irradiation 
+ 
+ 
+ 
+ 
+ + 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
0.30 
0.20 
0.02 
0.00 
0.49 
0.29 
0.03 
0.01 
100 
0.8 
IRRADIATION TIME (min) 
- Control 
-Control + 900 fig nicotine 
-0— Control + 450 ng nicotine 
-B— Control + 1350 ng nicotine 
Fig. 29. Time dependent generation of superoxide anion radical by varying concentrations 
of nicotine under UV light (254 nm); control = sodium phosphate buffer + 
Tween-20 + EDTA + NBT. 
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Fig. 30. Time dependent generation of superoxide anion radical by varying concentrations 
of nicotine under UV light (254 nm); control = sodium phosphate buffer + 
Tween-80 + EDTA + NBT. 
102 
10 20 30 40 50 60 70 
IRRADIATION TIME (min) 
80 90 
• Control 
•Control + 450 ^g nicotine 
-Control + ISO^gDNA 
-B—Control + 150 /ig DNA+ 450 lig nicotine 
Fig. 31. Time dependent generation of superoxide anion radical by nicotine under UV 
light (254 nm), in presence of DNA; control = sodium phosphate buffer + 
Tween-20 + EDTA + NBT. 
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Fig. 32. Time dependent generation of superoxide anion radical by nicotine under UV 
light (254 nm), in presence of DNA; control = sodium phosphate buffer + 
Tween-80 + EDTA + NBT. 
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The generation of the superoxide anion radical by nicotine was further confirmed 
by the use of superoxide dismutase, which is a specific quencher of the radical. Addition 
of SOD reduced the generation of the radical by riboflavin as well as by nicotine (Table 
15). 
Antigenic characteristics of nicotine and nicotine modified DNA 
The antigenic characteristics of nicotine, Nic*DNA (-Nic) and Nic*DNA (+Nic) 
were probed by inducing antibodies in rabbits. Direct binding ELISA was performed to 
detect the antibody response in rabbits following immunization with different 
immunogens. The anti-serum showed a titre of 1:12800 when Nic*DNA (-Nic) was used 
as an immunogen (Fig. 33). The titre was >I:25600 in case of Nic*DNA (+Nic) (Fig. 34). 
Immunization with nicotine alone resulted in poor immune response with a titre of 1:800 
(Fig. 35). 
Preimmune sera in all the three cases did not show appreciable binding with their 
respective immunogens. The antibodies against native DNA and UV irradiated DNA 
have already been raised in our lab. The results evaluated by direct binding ELISA 
showed little binding (Fig. 36). Further studies were carried on anti-Nic*DNA (-Nic) 
antibodies. 
Antigenic specificity of anti-Nic*DNA (-Nic) antibodies 
The specificity of the anti-Nic*DNA (-Nic) antibodies for antigenic determinants 
on Nic*DNA (-Nic) was evaluated by competitive binding assay. A maximum of 71.5% 
inhibition in antibody binding was recorded at 20 lig/ml concentration of Nic*DNA (-
Nic) when used as an inhibitor (Fig. 37). 
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Table 15 
Quenching of superoxide anion radical by superoxide dismutase 
Sample A560 Percent decrease in A560 
value after SOD addition 
Control + riboflavin 1.65 
Control + riboflavin + SOD 0.57 65.6 
Control + nicotine 1.18 
Control + nicotine + SOD 0.47 60.2 
Control = sodium phosphate buffer + EDTA + detergent + NBT. All the samples were 
UV irradiated at 254 nm. 
The data for A560 represent the arithmetic mean of duplicate samples. 
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-A— Preimmune sera O Immune sera 
Fig. 33. Direct binding ELISA of Nic*DNA (-Nic) with preimmune and immune sera. 
The microtitre plates were coated with 2.5/ig/ml of Nic*DNA (-Nic). 
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Fig, 34. Direct binding ELISA of Nic*DNA (+Nic) with preimmune and immune sera. 
The microtitre plates were coated with 2.5^g/ml of Nic*DNA (+Nic). 
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Fig. 35. Direct binding ELISA of nicotine with preimmune and immune sera. The 
microtitre plates were coated with 7.5/xg/ml of nicotine. 
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Fig. 36. Direct binding ELISA of vanous immune and preimmune sera with their 
respective immunogens 
no 
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Fig. 37. Inhibition ELISA of immune and preimmune serum antibodies with Nic*DNA (-
Nic). The microtitre plates were coated with 2.5^g/ml of Nic*DNA (-Nic) and 
the serum dilution was 1:100. 
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Purification and binding characteristics of immune IgG 
Immunoglobulin G was isolated from immune serum obtained from the rabbit 
immunized with Nic*DNA (-Nic). IgG was also isolated from the preimmune serum of 
the same rabbit. After isolating the IgG by affinity chromatography on Protein-A Agarose 
column (Fig. 38) its purity was evaluated by SDS-polyacrylamide gel electrophoresis in 
absence of a reducing agent. The purified IgG migrated as a single band upon 
electrophoresis (Fig. 38 inset). 
Direct binding ELISA of the purified immune IgG showed a strong reactivity with 
the immunogen (Fig. 39). Preimmune IgG as negative control showed negligible binding 
to Nic*DNA (-Nic). 
Band shift assay 
The visual detection of antigen-antibody interaction was performed by band shift 
assay. Constant amounts of nDNA and Nic*DNA (-Nic) were incubated with varying 
amounts of immune IgG for 2 hr at room temperature and overnight at 4°C. The resulting 
immune complexes were then electrophoresed on 1% agarose for 2 hr at 30 mA. 
Figure 40(b) shows the binding of IgG to Nic*DNA (-Nic). It is evident that with an 
increase in the amount of IgG, there was an increase in the formation of high molecular 
weight immune complexes, which resulted in retarded mobility with a subsequent 
decrease in fluorescence intensity of the antigen. 
Formation of the high molecular weight immune complexes between immune IgG 
and nDNA was not so evident (Fig. 40(a)). Binding of anti-Nic*DNA (-Nic) IgG to 
Nic*DNA (-Nic) was higher than its binding to nDNA. The results indicate specificity of 
immune IgG towards Nic*DNA (-Nic) in comparison to nDNA. 
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Fig, 38. Elution profile of anti-Nic*DNA (-Nic) IgG on Protein-A Agarose column. 
Inset: SDS-PAGE of purified IgG on 7.5% polyacrylamide gel. 
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Fig. 39. Direct binding ELISA of affinity purified preimmune and immune IgG with 
Nic*DNA (-Nic). The microtitre plate was coated with 2.5/ig/ml of Nic*DNA (-
Nic). 
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Fig. 40. Band shift assay of anti-Nic*DNA (-Nic) IgG binding to (a) nDNA and (b) 
Nic*DNA (-Nic). nDNA and Nic*DNA (-Nic) 1 ng eacfi were incubated witfi 
20 \xg , 4 0 l^ g , 60 |ig of the IgG for 2 hr at 37°C and overnight at 4°C. 
Electrophoresis was performed on 1% agarose gel for 2 hr at 30 mA. Lane 1 
contains native DNA (a) or Nic*DNA (-Nic) (b) while lanes 2, 3 and 4contain 
native DNA (a) or Nic*DNA (-Nic) (b) with increasing concentrations of the 
IgG. 
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Antibodies against native and nicotine modified DNA in smokers' sera 
To probe the possible role of nicotine in DNA damage due to smoking, binding of 
circulating antibodies in smokers' sera was assessed by direct binding ELISA. Smokers 
were classified into four categones, on the basis of their smoking index. The smoking 
index represents number of smoking days multiplied by number of cigarettes smoked per 
day, further multiplied by a factor of 10 .^ Category I consisted of smokers with smoking 
index 0-50, excluding 50; category II with smoking index 50-100, excluding 100; 
category III with index 100-200, excluding 200; while category IV consisted of smokers 
with smoking index 200 and above. Category IV corresponded to chain smokers. 
Never smokers' sera (NSS) were also tested. Since the never smokers were not 
exposed to cigarettes, their smoking index was zero. The sera from all the never smokers 
tested showed negligible binding to both native and nicotine modified DNA and served 
as negative control 
In total, 40 sera (10 from each category) were tested and all showed higher 
recognition of Nic* DNA (-Nic) over nDNA. Binding of sera from category I was low 
(Fig. 41), from category II was slightly higher (Fig. 42), from category III was 
moderately higher (Fig 43) and from category IV was excessively higher (Fig. 44). Table 
16 summarizes the binding pattern of all the sera It is evident from the table that 
exposure to cigarette results in increasing the number of circulating antibodies against 
DNA 
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Fig. 41. Direct binding ELISA of smokers' sera (with 0 < smoking index < 50) to nDNA 
and Nic*DNA (-Nic). Never smokers' sera (NSS) served as negative control. 
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Fig. 42. Direct binding ELISA of smokers' sera (with 50 < smoking index < 100) to 
nDNA and Nic*DNA (-Nic). Never smokers' sera (NSS) served as negative 
control. 
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Fig. 43. Direct binding ELISA of smokers' sera (with 100 < smoking index < 200) to 
nDNA and Nic*DNA (-Nic). Never smokers' sera (NSS) served as negative 
control 
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Fig. 44. Direct binding ELISA of smokers' sera (with smoking index > 200) to nDNA 
and Nic*DNA (-Nic). Never smokers' sera (NSS) served as negative control. 
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Table 16 
Antibodies binding of smokers' sera to native and nicotine modified 
DNA' 
Smoking index*^  No. of samples Absorbance with Absorbance with Nic* 
nDNA' DNA (-Nic)' 
0 4 0.09 ±.012 0.18 ±.020 
> 0 - < 5 0 10 0 14 ±.019 0.30 ±.021 
>50-<100 10 0.43 ±.030 0.59 ± .025 
>100-<200 10 0 61 ±.046 0.81 ±.024 
>200 10 0.84 ±.090 1.28 ±.090 
a Direct binding ELISA was performed with smokers' sera at 1:100 dilution. The 
microtitre plates were coated separately with native DNA and Nic*DNA (-Nic). 
b Smoking index represents number of smoking days multiplied by number of cigarettes 
smoked per day, further multiplied by a factor of lO'^ . Zero smoking index corresponds 
to never smokers while smoking index >200 corresponds to chain smokers. 
c Absorbance values reported as Mean ± SEM. 
Inhibition of the binding of antibodies in smokers' sera to Nic*DNA 
(-Nic) by native and nicotine modified DNA 
Inhibition studies were earned out in selective sera from each of the foui 
categories employing the technique of competition ELISA. Sera at 1.100 dilution weie 
allowed for competitive binding, using nDNA and Nic* DNA (-Nic) as inhibitors. All the 
sera showed higher inhibition with modified DNA than native DNA indicating higher 
specificity of circulating antibodies in smokers' sera towards modified DNA than the 
native one 
Inhibition ELISA was performed on four sera from category I. They showed little 
inhibition with both nDNA and Nic* DNA (-Nic) (Fig. 45, 46). In category II, two sera 
were tested for competitive binding and both showed moderate inhibition (24% and 30%) 
with Nic* DNA (-Nic). A relatively lower inhibition (18% and 20% respectively) was 
observed with nDNA (Fig. 47). Two sera were selected from category III. Both exhibited 
high inhibition (38% and 42%) with the modified DNA. Corresponding values with 
nDNA as an inhibitor were comparatively lower (20% and 25%) (Fig 48). Competitive 
binding studies were done on four sera from category IV. They all exhibited remarkably 
higher inhibition with nicotine modified DNA. One serum showed inhibition as high as 
73% The values for inhibition with native DNA were comparatively not so high (32%-
45%) (Fig 49, 50) These lesults have been summanzed in Table 17 
Recognition of native and modified DNA by circulating cancer 
antibodies 
The binding of native DNA and Nic*DNA (-Nic) to cancer sera was evaluated by 
using them as coating antigens in direct binding ELISA. The binding pattern was 
assessed at 1 100 serum dilution The study compnsed 45 sera from patients suffering 
from vanous cancers associated with smoking. Sera from normal healthy individuals 
served as control. Cancer sera were obtained after careful clinical examination of patients 
with histopathological diagnosis All the sera tested showed higher binding to the 
modified DNA over nDNA (Table 18) 
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Fig. 45. Detection of antibodies against nDNA and Nic*DNA (-Nic) in the sera # 3 and 4 
(with 0 < smoking index < 50). The microtitre plates were coated with 2.5/xg/ml 
ofNic*DNA(-Nic) 
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Fig. 46. Detection of antibodies against nDNA and Nic*DNA (-Nic) in the sera # 8 and 
10 (with 0 < smoking index < 50). The microtitre plates were coated with 
2 5ixg/m\ of Nic*DNA (-Nic) 
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Fig. 47. Detection of antibodies against nDNA and Nic*DNA (-Nic) in the sera # 4 and 
10 (with 50 < smoking index < 100). The microtitre plates were coated with 
2.5/xg/ml of Nic*DNA (-Nic). 
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Fig. 48. Detection of antibodies against nDNA and Nic*DNA (-Nic) in the sera # 2 and 8 
(with 100 < smoking index < 200). The microtitre plates were coated with 
2.5/ig/ml of Nic*DNA (-Nic). 
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Fig. 49. Detection of antibodies against nDNA and Nic*DNA(-Nic) in the sera # 1 and 2 
(with smoking index > 200). The microtitre plates were coated with 2.5/xg/mI of 
Nic*DNA (-Nic). 
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Fig. 50. Detection of antibodies against nDNA and Nic*DNA (-Nic) in the sera # 6 and 7 
(with smoking index > 200). The microtitre plates were coated with 2.5jLtg/ml of 
Nic*DNA (-Nic) 
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Table 17 
Inhibition of the binding of antibodies in smokers' sera to Nic*DNA 
(-Nic) by native DNA and nicotine modified DNA 
Category Sera number Maximum percent Maximum percent 
inhibition by nDNA inhibition by Nic*DNA 
at 20 i^g/ml (-Nic) at 20 [xg/ml 
I 3 17 18 
I 4 16 19 
I 8 12 15 
I 10 14 15 
II 4 18 24 
II 10 20 30 
III 2 20 38 
III 8 25 42 
IV 1 38 73 
IV 2 45 66 
IV 6 42 62 
IV 7 32 52 
The microtitre plates were coated with 2.5 Hg/ml of Nic*DNA (-Nic) and serum dilution 
was 1:100. 
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Table 18 
Comparison in the binding of antibodies in cancer sera to Nic*DNA (-
Nic) and native DNA 
Percent by which cancer sera showed higher binding to the modified DNA 
S No over native DNA 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Lung 
60 
45 
16 
84 
42 
3 2 
22 5 
8 5 
20 9 
10 9 
Oral cavity 
16 5 
45 5 
52 
91 
10 7 
184 
157 
9 9 
19.3 
18 1 
Cancer sera 
Head & Neck 
21.8 
14 1 
24 5 
12 3 
91 
26 5 
26 8 
0 07 
15 6 
194 
of 
Bladder 
64 7 
14 2 
30 4 
10 3 
47 8 
Larynx 
32 7 
15 5 
45 5 
69 7 
42 9 
Pharynx 
36 3 
55 3 
35 1 
193 
88 8 
The microtitre plates were coated with 2.5 ixg/ml of Nic=*-DNA (-Nic). 
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Out of the 45 sera collected, 10 were from lung cancer patients. All the 10 seia 
showed higher binding of antibodies towards Nic*DNA (-Nic) than nDNA (Fig. 51) 
Two sera showed appreciable difference (60% and 84%) between their binding to nDNA 
and Nic*DNA (-Nic). Four sera showed moderately higher binding (between 20%-45%) 
with modified DNA than native DNA. Four sera showed slightly higher binding with the 
modified DNA (3.2%, 8.5%, 10.9% and 16%). 
10 sera were collected from patients with oral cancer. Binding with modified 
DNA was much higher (52% and 91%) than that with nDNA in two sera, moderately 
higher (19.3%, 45.5%) in two sera and shghtly higher in remaining six sera (Fig. 52). 
Out of the 10 sera collected from patients with cancer of head and neck, one 
serum showed much higher (91%) recognition of Nic*DNA (-Nic) than that of nDNA, 
five sera showed moderately higher recognition (in the range of 19% to 27%), three sera 
showed slightly higher recognition (12.3%, 14.1% and 15.6%), while one serum showed 
negligibly higher recognition (0.07%) (Fig. 53). 
Among the 5 sera from patients with cancer of bladder, two showed much higher 
(64.7% and 47.8%) recognition of the modified DNA over native DNA, one showed 
moderately higher recognition (30.4%) and two showed slightly higher recognition 
(10.3% and 14 2%) (Fig. 54). 
Out of the 5 sera from patients suffenng from cancer of larynx, one exhibited 
much higher (69.7%) recognition, three exhibited moderately higher (32.7%, 42.9%, 
45 5%) and one exhibited slightly higher (15.5%) binding with nicotine modified DNA 
than native DNA (Fig 55). 
Among the 5 sera collected from patients with cancer of pharynx, two exhibited 
much highei (55.3% and 88 8%) and three exhibited moderately higher recognition of 
Nic*DNA (-Nic) than nDNA (Fig. 56). 
All these results have been summanzed in Table 18. 
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Fig. 51. Binding of sera of lung cancer patients to nDNA and Nic*DNA (-Nic). NoiTnal 
human sera (NHS) served as negative control. The value shown for NHS is the 
mean absorbance value of 4 samples. 
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Fig. 52. Binding of sera of oral cancer patients to nDNA and Nic*DNA (-Nic). Normal 
human sera (NHS) served as negative control. The value shown for NHS is the 
mean absorbance value of 4 samples. 
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Fig. 53. Binding of sera from patients with cancer of head and neck to nDNA and 
Nic*DNA (-Nic). Normal human sera (NHS) served as negative control. The 
value shown for NHS is the mean absorbance value of 4 samples. 
[34 
SERA NUMBER 
DnDNA INic*DNA(-Nic) 
Fig. 54. Binding of sera from patients with cancer of bladder to nDNA and Nic*DNA (-
Nic). Normal human sera (NHS) served as negative control. The value shown 
for NHS is the mean absorbance value of 4 samples. 
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Fig, 55. Binding of sera from patients with cancer of larynx to nDNA and Nic*DNA (-
Nic). Normal iiuman sera (NHS) served as negative control. The value shown 
for NHS is the mean absorbance value of 4 samples. 
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Fig. 56. Binding of sera from patients with cancer of pharynx to nDNA and Nic*DNA (-
Nic). Normal human sera (NHS) served as negative control. The value shown 
for NHS is the mean absorbance value of 4 samples. 
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Inhibition of the binding of antibodies in cancer sera to Nic*DNA (-Nic) 
by nDNA and Nic*DNA (-Nic) 
The binding specificity of antibodies in cancer sera were analysed by using the 
technique of competition ELISA (Table 19) Two sera from lung cancer patients were 
tested and both showed higher inhibition with modified DNA than with nDNA. One 
serum showed a very high inhibition of 76% with Nic*DNA (-Nic) (Fig. 57). In oral 
cancer category, two sera were tested for competitive binding and both showed higher 
inhibition of 42% and 53% with Nic*DNA (-Nic). Both sera showed a relatively lower 
inhibition with nDNA (Fig. 58). In head and neck cancer category, out of the two sera 
tested, one showed remarkably high inhibition of 63% with Nic*DNA (-Nic) while other 
showed inhibition of 45%. With native DNA, they showed inhibition of 41% and 31% 
respectively (Fig. 59). One serum, each from cancer of bladder, (Fig. 60), larynx (Fig. 61) 
and pharynx (Fig. 62) was tested. All the three sera showed higher inhibition with 
Nic*DNA (-Nic) (48%, 57%, 39%) than native DNA. The values of inhibition with 
nDNA were 39%, 49% and 28% respectively. All these results have been summanzed in 
Table 19. 
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0.01 0.10 1.00 10.00 
INHIBITOR CONCENTRATION (/ig/ml) 
100.00 
-B— sera#9 with nDNA 
-A—sera#6 with nDNA 
•sera#9 with Nic*DNA(-Nic) 
-sera#6 with Nic*DNA(-Nic) 
Fig. 57. Detection of antibodies against nDNA and Nic*DNA (-Nic) in the sera # 6 and 9 
of patients with lung cancer The microtitre plates were coated with 2 Spig/ml of 
Nic*DNA (-Nic) 
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Fig. 58. Detection of antibodies against nDNA and Nic*DNA (-Nic) in the sera # 9 and 
10 of patients with oral cancer The microtitre plates were coated with 2.5^g/ml 
ofNic*DNA(-Nic). 
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Fig. 59. Detection of antibodies against nDNA and Nic*DNA (-Nic) in the sera # 5 and 6 
of patients with cancer of head and neck. The microtitre plates were coated with 
2.5/ig/ml of Nic*DNA (-Nic). 
141 
§ 50.00 
^ 60.00 
80.00 
0.01 0.10 1.00 10.00 
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Fig. 60. Detection of antibodies against nDNA and Nic*DNA (-Nic) in the sera # 2 of 
patient with cancer of bladder. The microtitre plates were coated with 2.5/ig/ml 
of Nic*DNA (-Nic). 
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Fig. 61. Detection of antibodies against nDNA and Nic*DNA (-Nic) in the sera # 2 of 
patient with cancer of larynx. The microtitre plates were coated with 2.5/xg/ml of 
Nic*DNA (-Nic). 
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Fig. 62. Detection of antibodies against nDNA and Nic*DNA (-Nic) in the sera # 4 of 
patient with cancer of pharynx. The microtitre plates were coated with 2.5/xg/ml 
ofNic*DNA(-Nic). 
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Table 19 
Inhibition of the binding of antibodies in cancer sera to Nic*DNA (-Nic) 
by native DNA and nicotine modified DNA 
Type of cancer 
Lung 
Lung 
Oral 
Oral 
Sera number 
6 
9 
9 
10 
Maximum percent 
inhibition by nDNA 
at 20 ng/ml 
29 
39 
31 
33 
Maximum percent 
inhibition by Nic*DNA 
(-Nic) at 20 jig/ml 
32 
76 
42 
53 
Head and neck 
Head and neck 
Bladder 
Larynx 
Pharynx 
2 
4 
41 
31 
39 
49 
28 
63 
45 
48 
57 
39 
The microtitre plates were coated with 2.5 |ig/ml of Nic*DNA (-Nic) and serum dilution 
was 1:100. 
(Discussion 
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Nicotine is an alkaloid, which is present in tobacco and a wide variety of other 
plants (Castro and Monji, 1986; Sheen, 1988; Davis et al., 1991; Gupta et al, 1996). The 
introduction of nicotine as a therapeutic agent against diverse pathological and 
physiological conditions resulted in the widespread exposure of people to nicotine, and 
the subsequent recognition of the pleasurable effects of tobacco consumption. Non-
smokers are exposed to nicotine through plant material and side-stream tobacco smoke 
(Hoffmann et al, 1985; Castro and Monji, 1986; Sheen, 1988; Pacific! et al, 1995). In 
recent years, the use of nicotine in the form of chewing nicotine polacrilex, transdermal 
nicotine, nasal spray, sublingual tablet, and oral inhaler has been developed to treat 
people suffering from certain diseases or as an aid for smoking cessation (Henningfield, 
1995; Benowitz et al., 1998; Molander and Lunell, 2001). Nicotine is also used as an 
insecticide in agriculture. This shows that human population is all the time exposed to 
nicotine in one way or the other. 
According to the Worid Health Organisation (WHO) tobacco smoking is the most 
important cause of preventable death. The American Psychiatric Association and WHO 
classify tobacco dependence as a disease. Tobacco smoking is not only a disease in itself 
but can also cause other diseases, such as chronic obstructive lung disease, lung cancer 
and cardiovascular disease, and can worsen pre-existent disease, e.g. asthma (Nardini et 
al, 2001). Many studies have reported negative consequences of nicotine on the 
cardiovascular, pulmonary, gastrointestinal, urogenital, pancreatic, and nervous systems 
(Goldman and Klinger, 1998; Roy et al, 1998; Kavitharaj and Vijayammal, 1999). The 
use of nicotine continues despite reports correlating nicotine with alterations of the 
immune system (McAllister-Sistilli et al, 1998; Froen et al, 2000; Singh et al, 2000), 
potential increases in cancer (Wright et al, 1993; Heusch and Maneckjee, 1998), and 
contributions to cardiovascular disease (Benowitz, 1997b; Feuerstein, 1999). Nicotine is a 
natural agonist of the nAChRs (Hakki et al, 2001) and binds stereospecifically to 
acetylcholine receptors in the periphery and central nervous system leading to behavioral, 
cardiovascular, neuromuscular, endocrine, and metabolic effects (Maneckjee and Minna, 
1990). The effects of nicotine that are associated with its dependence include increased 
expression of brain nicotine receptors, changes in regional brain glucose metabolism. 
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encephalographic changes, the release of catecholamines, tolerance, and physiologic 
dependence (Henningfield et al, 1995) 
Although, the use of NRT has become popular in recent years these products ha\e 
been found to be associated with many contradictions and adverse effects. Moreover, 
nicotine medication alone is not sufficient. The therapy should include instructions, 
follow-up and intervention by physicians (Henningfield, 1995). Smobng cessation 
counseling should be given to healthy subjects and even more vigorously to patients with 
manifested disease (Meinertz and Heitzer, 2002). 
Many studies have shown that nicotine may produce its effects via the production 
of oxygen radicals (Murohara et al, 1994; Kodama et al, 1997; Mayhan and Sharpe, 
1998a; 1998b; 1999, Mayhan et al, 1999; Kurahashi et al, 2001; Chong et al, 2002, Qin 
et al, 2003). The damage from these free radicals has been proposed to be involved in 
carcinogenesis and vanous degenerative diseases (Halliwell and Aruoma, 1991; Ames et 
al, 1995; Pryor, 1997). ROS modify DNA at vanous sites that include base damage 
(Dizdaroglu et al, 1991) leading to mutations (Moody and Hasan, 1982; Brawn and 
Fndovich, 1985). 
Tobacco smoke is an established human carcinogen that contains more than 50 
carcinogens (Shields, 2000). Though some scientists do not consider nicotine to be 
carcinogenic (Hecht, 1999, Sopon, 2002), many of them associate nicotine with cancer 
and consider it as pro-angiogenic, cancer promoter, and tumor promoter (Wnght et al, 
1993; Maneckjee and Minna, 1990; 1994; Villablanca, 1998; Hakki et al, 2001, Minna, 
2003). Reports are available which associate nicotine with vanous types of cancers e g 
cancer of lung, pancreas and bladder (Rayford, 2001; Masuda et al, 2001; Zeegers et al, 
2002; Song era/., 2003). 
Although nicotine has been implicated as a potential factor in the pathogenesis of 
cancer in humans, its mechanism of action in the development of cancer remains largely 
unknown (Sugano et al, 2001). Among the vanous proposed mechanisms, some are 
inhibition of apoptosis (Wnght et al, 1993; Heusch and Maneckjee, 1998), enhancement 
of angiogenesis (Villablanca, 1998, Heeschen et al, 2001; 2002), enhancement of 
production of ROS (Kodama et al, 1997), stimulation of VEGF (Conklin et al, 2002) 
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and growth factor-mediated mechanisms (Rakowicz-Szulczynska et al, 1994). Besides 
contributing to carcinogenesis nicotine exposure also results in a decrease in efficacy of 
anticancer treatment (Onoda et al., 2001; Chen et al, 2002). 
In the present study, calf thymus DNA was modified by nicotine under UV 
irradiation (254 nm). UV absorption spectra of nicotine showed a main sharp peak at its 
?imax (260 nm), a major shoulder at 255 nm, and a minor shoulder at 263 nm. Factors 
such as UV irradiation dose, dialysis, nicotine concentration, incubation time and pH 
were taken into account while standardizing the protocol of DNA modification by 
nicotine. UV irradiation brought remarkable changes in absorption patterns of nicotine as 
well as DNA modified by nicotine. Both showed blue shift in their Xmax and Xmin and 
hyperchromicity at both the wavelengths in a dose dependent manner. However, no 
remarkable change could be observed in the absorption profile of nicotine modified DNA 
over a range of pH, which ruled out the possibility of any electrostatic interaction 
between DNA and nicotine. Dialysis of nicotine modified DNA also resulted in 
substantial changes in the absorption profile. Thus, for antigen preparation, DNA was 
mixed with nicotine; UV irradiated for 60 min and then extensively dialysed to remove 
nicotine. The antigen prepared in such fashion, Nic*DNA (-Nic), was used throughout 
the study, unless mentioned otherwise. However, in some studies including immunization 
Nic*DNA (+Nic) was also used, which was prepared without dialysis. 
Modification of DNA by nicotine resulted in hypochromicity of the spectral curve 
of Nic*DNA (-Nic) as well as a shift in minima when compared to that of nDNA. This 
could be attributed to single strand breaks and modification of nitrogenous bases, which 
results in destruction of the chromophoric groups as revealed by hypochromicity of 
Nic*DNA (-Nic). The fluorescence spectra of Nic*DNA (-Nic) showed decrease in 
fluorescence intensity as compared to native DNA, which indicates the generation of 
strand breaks as lesser amount of ethidium bromide could be intercalated in modified 
DNA as compared to native DNA. 
The thermal denaturation profiles of nDNA and Nic*DNA (-Nic) showed a net 
decrease of 8°C in the Tm value for Nic*DNA (-Nic) as compared to its native conformer 
indicating the presence of single stranded regions and base modification in the modified 
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DNA, and also a partial destruction in its secondary structure. Base stacking and 
hydrogen bonding interactions are known to stabilize the native structure of DNA, thus 
high temperature that disrupts these interactions favors denaturation of DNA (Casperson 
and Voss, 1983; Thomas, 1993). The lowered melting temperature of Nic*DNA (-Nic), 
therefore points towards the destabilization of these interactions and consequently helix 
disruption. Structural alterations were caused in Nic*DNA (-Nic) due to simultaneous 
strand scission, generation of single stranded regions, and disruption of hydrogen 
bonding. 
Generation of single strand breaks in nicotine modified DNA was further 
confirmed by hydroxyapatite column chromatography, which discriminates nucleic acids 
endowed with different secondary structures, with rigid, ordered structures having more 
affinity for the matrix than flexible, disordered ones (Bemardi, 1965; 1969). Native DNA 
eluted as a single peak at the higher strength buffer (250 mM Na-K-phosphate) indicating 
its greater affinity for hydroxyapatite matrix and hence presence of double strandedness 
as well as a regular and intact secondary structure. In contrast, elution profile of 
Nic*DNA (-Nic) showed an additional minor peak at the lower strength buffer (125 mM 
Na-K-phosphate), which indicates presence of single stranded regions and a resultant 
local perturbation in the secondary structure of Nic*DNA (-Nic). 
Earlier studies demonstrate that the structural alteration in DNA following 
damage by various agents may be large enough to be recognized by single strand specific 
nucleases (Slor and Lev, 1973; Kato and Fraser, 1973; Shishido and Ando, 1974; 
Yamasaki et al., 1977). In view of this, nDNA and Nic*DNA (-Nic) were subjected to 
nuclease SI digestion. The results showed partial digestion of Nic*DNA (-Nic) on 
treatment with nuclease SI, while native DNA remained undigested. This observation 
clearly demonstrates that sufficient distortions are caused in the helical structure of DNA 
on modification by nicotine, rendering it susceptible to digestion by single strand specific 
nuclease SI. 
Nicotine generated superoxide radical when exposed to UV light. However, when 
exposed to fluorescent light the radical generation was not observed. The generation of 
the radical was found to be directly proportional to nicotine concentration. Quenching 
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with superoxide dismutase (SOD), the specific enzyme that dismutates Oi' (Sies and 
Menck, 1992) was done to confirm the generation of the radical by nicotine. 
Native DNA per se is known to be a poor immunogen (Madaio et al., 1984; 
Stollar, 1986). However, its oxidatively damaged analog with altered bases and 
conformational variance from B-form can trigger immune response (Lafer et al., 1981; 
Lee et al, 1984; Santella et al., 1985; Sundquist et al., 1987; Moinuddin and Ali, 1994; 
Hasan et al., 1995). Double-stranded RNA, RNA-DNA hybrid, left handed Z-DNA, 
triple helical RNA and DNA analogues, double helical polydeoxyribonucleotides, DNA 
modified with drugs, hormones, chromatin or DNA in complexes with binding proteins 
induce antibodies (Stollar 1973; 1975, 1986; Anderson et al., 1988a; Desai et al., 1993; 
Moinuddin and Ali, 1994; Hasan et al., 1995; Theofilopoulos, 1995; Arjumand, et al., 
1995; 1997; Arif and Ali, 1996). 
Nic*DNA (-Nic), Nic*DNA (+Nic) and nicotine were used as immunogens to 
induce antibodies in rabbits. Preimmune sera in all the three cases did not show 
appreciable binding with their respective immunogens. Immunization with nicotine alone 
resulted in poor immune response with a low titre of 1:800. Immunization with Nic*DNA 
(-Nic) resulted in high immune response inducing high antibodies titre (1:12800). The 
highest titre (>1:25600) was obtained in case of Nic*DNA (+Nic). 
The DNA was modified using two factors, nicotine and UV irradiation. It has 
already been shown by other investigators in our lab. that nDNA as well as DNA 
modified by UV irradiation show poor immune response. Thus, the factor responsible for 
induction of high immune response by Nic*DNA (-Nic) appears to be modification by 
nicotine. Studies have also demonstrated that the antigenic stimulus for the generation of 
antibodies against DNA involves a substance other than DNA or a conformational 
variance from the B-form (Burlingame et al., 1993; Mohan et al., 1993). Thus, the 
presence of nicotine in Nic*DNA (-i-Nic) appears to be the reason which made Nic*DNA 
(+Nic) a better immunogen over Nic*DNA (-Nic). However, when Nic*DNA (-Nic) was 
used as an immunogen, nicotine was removed prior to immunization. This further 
confirms that the strong immunogenicity of Nic*DNA (-Nic) was only due to the 
modification of DNA by nicotine. 
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The specificity of the anti-Nic*DNA (-Nic) antibodies for antigenic determinants 
on Nic*DNA (-Nic) was evaluated by competitive binding assay. A maximum of 71.5% 
inhibition in antibody binding was recorded at 20 [ig/m\ concentration of Nic*DNA (-
Nic) when used as an inhibitor. Direct binding ELISA of the purified anti-Nic*DNA (-
Nic) immune IgG showed a strong reactivity with the immunogen. Preimmune IgG as 
negative control showed negligible binding to Nic*DNA (-Nic). The specificity of the 
anti-Nic*DNA (-Nic) immune IgG was further confirmed by band shift assay, which 
showed that binding of anti-Nic*DNA (-Nic) IgG to Nic*DNA (-Nic) was higher than its 
binding to nDNA. The results, thus, indicate higher specificity of immune IgG towards 
Nic*DNA (-Nic) in comparison to nDNA. 
Although many studies have demonstrated that cigarette smoke damages the DNA 
by forming single-strand breaks or through modification of bases (Asami et al, 1996; 
Yoshie and Ohshima, 1997), little literature is available explaining the direct role of 
nicotine in DNA damage. However, it has been proposed that nicotine is one of the key 
constituents of tobacco smoke causing adverse health effects (Benowitz 1986; 1997a; 
Benowitz and Gourlay, 1997; Zevin et al., 1998) and that nicotine plays a major role in 
mediating the pharmacological, biochemical, psychological, and other effects of cigarette 
smoking (Dursun and Kutcher, 1999), whether nicotine exposure can lead to any DNA 
damage in smokers is still not certain. To probe the possible role of nicotine in DNA 
damage due to smoking, binding of circulating antibodies in smokers' sera was assessed 
by direct binding ELISA. 40 sera were tested from smokers with varying smoking index 
and all showed higher recognition of Nic* DNA (-Nic) over nDNA. The binding of Nic* 
DNA (-Nic) to the circulating antibodies in various sera was found to be directly 
proportional to the smoking index of the smokers e.g. chain smokers showed maximum 
recognition of the modified DNA while occasional smokers showed lesser recognition. 
Never smokers' sera (NSS) were also tested and all the never smokers tested showed 
negligible binding to both native and nicotine modified DNA. These results clearly 
indicate that exposure to cigarette results in increasing the number of circulating 
antibodies against DNA and that too in a dose dependent manner. Moreover, competition 
ELISA results also showed preferential binding of all the sera tested to Nic*DNA (-Nic) 
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in comparison to nDNA. The higher inhibition with modified DNA than native DNA 
indicates higher specificity of circulating antibodies in smokers' sera towards modified 
DNA than the native one. 
Tobacco smoke may be involved in mitochondrial production of ROS, which 
have the potential to cause DNA damage (Leanderson and Tagesson, 1990; 1992). 
Oxidative DNA damage is postulated to be a major event in the development of various 
cancers. Increased levels of circulating antibodies and autoantibodies have been reported 
in sera of patients with malignancies (Anderson et al., 1988b; Faiderbe et al., 1992; 
Chagnaud et al., 1992; Becker et al, 1994). Elevated levels of anti-nuclear antibodies up 
to 27% in cancer have been reported (Zeronski et al., 1972; Bunham, 1972). In the 
present study, sera of cancer patients were tested for the presence of antibodies reactive 
towards native and Nic*DNA (-Nic). The study comprised of 45 sera from patients with 
various types of cancers associated with smoking. Sera from normal healthy individuals 
served as control. In direct binding ELISA, almost all the cancer sera tested showed 
higher recognition of Nic*DNA (-Nic) by the circulating antibodies. The antigenic 
specificity of circulating antibodies in selected sera was analyzed by competition binding 
assay. All the sera showed higher inhibition with nicotine modified DNA than native 
DNA indicating higher specificity of circulating antibodies in cancer patients' sera 
towards modified DNA than the native one. 
The data presented here clearly indicates the presence of circulating antibodies in 
cancer sera reactive to Nic*DNA (-Nic) and native DNA. All the sera tested from lung 
and oral cancer patients showed higher recognition of Nic*DNA (-Nic) as compared to 
native DNA. These patients have history of smoking and support for strong oxidative 
stress in vivo. It has been reported that lung and oral carcinomas are strongly correlated 
with oxidative DNA damage (Olinski et al., 1992; Okamoto et al., 1994). Higher 
recognition of Nic*DNA (-Nic) over nDNA by circulating antibodies in these patients 
supports that DNA in these patients was some how oxidatively damaged. Of the 10 head 
and neck cancer sera tested all showed higher reactivity with Nic*DNA (-Nic) as 
compared to its native analog. The results obtained from patients with cancer of bladder, 
larynx, and pharynx show that the circulating antibodies in the sera of these patients have 
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more preference for Nic*DNA (-Nic) as compared to nDNA thus, suggesting the role of 
damage by nicotine to DNA in the development of these cancers. 
It has been well accepted that ROS damage to DNA plays a fundamental role in 
carcinogenesis (Malins and Haimanot, 1991; Malins et al., 1996). Oxidative DNA 
damage resulting from active oxygen species has been shown to play a critical role in 
several biological processes including cancer and autoimmune diseases (Cerutti, 1985; 
Ames, 1989). Out of the various cancer sera tested in the present study, a large group 
belonged to patients suffering from malignancies of respiratory system, such as cancer of 
larynx, lung and oral cavity. The primary cause of these malignancies involves addiction 
to tobacco (chewing and smoking), which is quite prevalent in India and is known to 
enhance production of ROS in vivo (Nair et al., 1992; Leanderson, 1993). Hence ROS is 
implicated in etiology of malignancies of respiratory system (Wyder and Hoffman, 
1994). Results of the present investigation showed that ROS (particularly superoxide 
radicals) were generated during the modification of DNA by nicotine. Thus, modification 
of DNA by nicotine appears to be the reason for higher recognition and more specificity 
of circulating antibodies in the sera of smokers and cancer patients towards nicotine 
modified DNA than towards its native analog. Generation of ROS during the process of 
DNA modification by nicotine under UV light might have further enhanced the extent of 
higher recognition of modified DNA. 
Conclusion 
Based on this study, the following conclusions can be drawn: 
1. UV irradiation of DNA in presence of nicotine results in structural alterations 
such as single stand breaks, disruption of hydrogen bonds and a consequent 
helix destabilization. 
2. The extent of DNA damage by nicotine is directly proportional to nicotine 
concentration and UV irradiation dose. However, it is independent of 
incubation time and pH, which rules out the possibility of electrostatic 
interaction between DNA and nicotine. 
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3. Nicotine modified DNA is found to be thermally less stable than its native 
analog. 
4. Nicotine generates superoxide anion radical on UV irradiation. However, it 
cannot generate the radical under fluorescent light. 
5. Nicotine induces certain conformational changes in DNA, rendering it highly 
immunogenic in experimental animals. 
6. Nicotine modified DNA when injected in presence of nicotine [Nic*DNA 
(+Nic)] shows a better immune response than that in absence of nicotine 
[Nic*DNA (-Nic)]. Presence of nicotine in the former makes it a better 
immunogen than the latter. 
7. Similar to nDNA and UV irradiated DNA, nicotine is also found to be a poor 
immunogen. 
8. The induced antibodies are found to be specific for their respective 
immunogens. 
9. Circulating antibodies in the sera of smokers with different smoking status, 
varying from never smoker to chain smokers showed preferential binding for 
Nic*DNA (-Nic) than nDNA. 
10. Antibodies in sera of various cancer patients were found to be more specific 
for Nic*DNA (-Nic) than for its native analog. 
Future perspective 
Tobacco shows numerous adverse effects on human body. And it is rightly called 
as "the addictive slow poison" (Gupta and Sen, 2001). Addiction of nicotine compels 
people to use tobacco and thus results in their exposure to a wide range of toxins and 
carcinogens present in tobacco, as shown in Fig. 3. Blocking any of the vertical pathways 
as shown in the figure may lead to reduced lung cancer incidence and mortality. 
Preventing nicotine addiction and improving smoking cessation strategies are clearly 
priorities, but these are only partially successful (Hurt et al, 1994; Hughes, 1996; 
Emmons et al, 1997). An important approach for addicted smokers and ex-smokers is 
chemoprevention. Many agents that can block carcinogen activation or enhance 
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detoxification are known to prevent carcinogenesis (Hecht, 1997) Other 
chemopreventive compounds inhibit events downstream from DNA adduct formation 
Development of additional effective chemopreventive agents should be a major pnonty 
for reducing lung cancer incidence (Hecht, 1999) 
Inhibition of apoptosis by nicotine has been associated with cancer (Wnght et al, 
1993) The nicotinic acetylcholine receptor antagonists, hexamethonium and 
decamethonium, reverse the nicotine induced suppression of apoptosis. This represents a 
new strategy for treatment and prevention of cancer using nicotinic receptors antagonists 
(Maneckjee and Minna, 1994). 
Exposure of NNN and NNK, which are metabolites of nicotine results in DNA 
strand breaks Vitamin E, beta-carotene, SOD, catalase and mannitol reduce the DNA 
damage, indicating a role of oxygen radicals in the mediation of the damage (Altmann et 
al, 1984; Weitberg and Corvese, 1997). A possible approach to the chemoprevention of 
tobacco-induced carcinogenesis is an active area of research. 
Although nicotine is a well-known therapeutic agent in many diseases, its use is 
associated with many side effects Development of novel nicotinic agonists may provide 
for greater efficacy and reduced side effects. With increased understanding of the 
molecular biology of the nicotinic acetylcholine receptor new molecules are being 
developed which have enhanced selectivity for nicotinic receptor subtypes or which may 
be allostenc modulators of nicotinic receptor function. One of these is ABT-418 Other 
nicotinic agonists under development include GTS-21, an anabaseine denvative and S-
1663 Aside from their potential therapeutic efficacy with Alzheimer's and Parkinson's 
diseases, novel nicotinic acetylcholine receptor may have potential in treating benign 
familial neonatal convulsions and as analgesics. Understanding the regulatory role of 
nicotine receptors and their underlying molecular and cellular biology may lead to a new 
era in the development of selective nicotinic agents for a vanety of disease states (Perkins 
et al, 1996) Another strategy includes combining mecamylamine, a nicotine antagonist, 
with nicotine patch The rationale behind the combination of these medications is that by 
using both medications a greater number of nicotinic receptors would be occupied, 
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producing a greater attenuation of the rewarding effects of nicotine (Heishman et al, 
1997). 
Individuals lacking full functional CYP2A6, who therefore have impaired 
nicotine metabolism, are significantly protected against becoming tobacco-dependent 
smokers. Individuals carrying CYP2A6-null alleles may also have a decreased risk of 
developing tobacco-related cancers (Law et al, 1997). Since genetic variation in 
CYP2A6 decreases nicotine metabolism and smoking, manipulating this enzyme could 
be used therapeutically in prevention and treatment of smoking as well as in exposure 
reduction (Tyndale et al, 1999). 
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